

Regulation and involvement of matrix metalloproteinases in vascular diseases

Matthew Amin¹, Sathnur Pushpakumar¹, Nino Muradashvili¹, Sourav Kundu¹, Suresh C. Tyagi¹, Utpal Sen¹

¹Department of Physiology and Biophysics, University of Louisville, School of Medicine, Louisville, KY-40202

TABLE OF CONTENTS

1. Abstract
2. Introduction
3. General concepts of MMPs
4. Structure and biosynthesis
5. Types of MMPs and their involvement in diseases
 - 5.1. Collagenases
 - 5.2. Gelatinases
 - 5.3. Stromelysins
 - 5.4. Membrane-type MMPs
 - 5.5. Matrilysins
 - 5.6. Enamelysin
 - 5.7. Metalloelastase
 - 5.8. Unclassified MMPs
6. Regulation of MMPs in vascular diseases
 - 6.1. Biological Activators of MMPs
 - 6.2. Natural inhibitors of MMPs: tissue inhibitor of metalloproteinases (TIMPs)
 - 6.3. Epigenetic regulation of MMPs
 - 6.4. miRNA regulation of MMPs
 - 6.5. Pharmacological inhibitors of MMPs
7. Summary and conclusions
8. Acknowledgements
9. References

1. ABSTRACT

Matrix metalloproteinases (MMPs) are a family of zinc dependent endopeptidases whose main function is to degrade and deposit structural proteins within the extracellular matrix (ECM). A dysregulation of MMPs is linked to vascular diseases. MMPs are classified into collagenases, gelatinases, membrane-type, metalloelastase, stromelysins, matrilysins, enamelysins, and unclassified subgroups. The production of MMPs is stimulated by factors such as oxidative stress, growth factors and inflammation which lead to its up- or down-regulation with subsequent ECM remodeling. Normally, excess activation of MMPs is controlled by their endogenous inhibitors, tissue inhibitors of metalloproteinases (TIMPs). An imbalance of MMPs and TIMPs has been implicated in hypertension, atherosclerotic plaque formation and instability, aortic aneurysms and varicose vein wall remodeling. Also, recent evidence suggests epigenetic regulation of some MMPs in angiogenesis and atherosclerosis. Over the years, pharmacological inhibitors of MMPs have been used to modify or prevent the development of the disease with some success. In this review, we discuss recent

advances in MMP biology, and their involvement in the manifestation of vascular disease.

2. INTRODUCTION

Vascular diseases are the leading cause of morbidity and mortality worldwide. In general, vascular disease relates to pathological states of the circulatory system including arteries, vein, capillaries, lymph vessels, and blood disorders which affects circulation. One of the major manifestation of vascular disease is atherosclerosis, a plaque build-up containing fat, cholesterol, and other substances within the arterial walls. Over time, the plaque hardens leading to narrowing of the arterial lumen which ultimately decreases blood flow to the tissue or organ. The consequence of atherosclerosis can progress to a spectrum of serious health problems including hypertension, stroke, heart attack and death.

The inner lining of blood vessels is composed of endothelial cells (ECs) and damage to ECs by pathogens or oxidative radicals lead to inflammatory response which

triggers leukocyte adhesion and transmigration into the vessel wall. As a result, extracellular matrix regulatory peptidases, matrix metalloproteinases (MMPs) become activated leading to vascular smooth muscle cells (VSMCs) proliferation, cell-to-cell tight junction protein alteration and vascular leakage, elastin and collagen derangement, and vascular dysfunction. This review, summarizes the impact of uncontrolled MMP activation in the vasculature and highlights their regulatory mechanisms involved in maintaining physiological function and deviations leading to pathophysiology.

3. GENERAL CONCEPTS OF MMPs

In 1962, Gross and Lapiere discovered an enzyme capable of degrading collagen during the metamorphosis of the anuran tadpole tail (1). The enzyme, a collagenase was found to play a significant role in the normal development and growth in amphibians thus maintaining a balance between tissue synthesis and degradation (1). From this conclusion arose the general concept of MMPs which has been applied continuously in various studies including homeostasis and tissue remodeling under pathological conditions. The MMPs in turn are regulated by a group of enzymes, tissue inhibitors of metalloproteases (TIMPs). The general concept dictates that a balance between TIMPs and MMPs regulates tissue remodeling, repair, and resorption. A dysregulation of the MMP/TIMP ratio may lead to unchecked MMP activity leading to adverse events in tissue homeostasis (2). There are currently 25 MMPs with substrate specificity for a broad spectrum of fibrous structural proteins (2). Many of these substrates are found within the extracellular matrix (ECM) surrounding the blood vessels (3). Indeed, dysregulated MMP activity has been observed in a number of diseases including atherosclerosis, fibrosis, heart failure, emphysema, and chronic obstructive pulmonary disease (COPD) where ECM alteration is a predominant feature (2,4). Since MMP activity is known to play a prominent role in vascular diseases a potential strategy counter would be to reduce MMP activity to ameliorate ECM remodeling.

4. STRUCTURE AND BIOSYNTHESIS

X-ray crystallography and NMR spectroscopy have been used for elucidation of MMP structure in the last 20 years. Prior to this, thermolysin, a bacterial endopeptidase, and astacin, a crayfish endopeptidase, were used to design MMP inhibitors and subsequent structure elucidation. However, the models lacked the information necessary to carry out rational drug design, and the catalytic domain of MMP-1 became the first of the group to undergo structural studies using multiple isomorphous replacements at a resolution of 2.4 Angstroms (5). MMPs have three conserved domains; (i) zinc-containing catalytic domain; (ii) pro-peptide on the amino terminus; (iii) hemopexin-like domain at the

C-terminus (Figure 1). The catalytic domain has two zinc ions and at least one calcium ion. Of the zinc ions, only one ion (Z1) is catalytic (2). MMP-23 does not have a catalytic domain (2). The hemopexin-like domain is called as such because of its sequence homology to hemopexin, a plasma protein involved in heme binding and transport (2). MMPs are a family of zinc endopeptidases present in the extracellular matrix (ECM) or membrane (2). Sequence alignment has confirmed that they belong to a superfamily of zinc peptidases known as metzincins. Among all the MMPs described so far, 25 MMPs have been discovered where MMP-4, -5, and -6 are encoded by MMPs can be either membrane-bound or secreted (2,6,7). Membrane-type MMP is often referred to as simply MT-MMPs (2).

All MMPs are secreted and cleavage of the signal sequence yields a zymogen inactivated by a highly conserved prodomain displaying the consensus sequence PRCGVPDV (Figure 1). This prodomain is often called a switch loop as it contains Cys92 whose thiol coordinates with Z1 in the proenzyme (2,8). The polypeptide linker connecting the catalytic domain to the prodomain can undergo furin cleavage, proconvertase action, sheddase action, or auto-activation to yield the active enzyme (2).

5. TYPES OF MMPs AND THEIR INVOLVEMENT IN DISEASES

MMPs are further divided into subgroups based on their substrate preference (Figure 2). Blood vessels are known to be under the control of hormonal, neuronal, and hemodynamic input. Since the blood vessels are surrounded by ECM, dysregulation of MMP activity may lead to chronic vascular remodeling and vascular disease (9). Table 1 displays the vascular events associated with specific MMPs.

5.1. Collagenases

MMP-1, -8 -13 and -18 are collagenases which mainly cleave fibrillar collagen types I, II and III. In addition, these collagenases exhibit specificity for other substrates such as gelatin, casein, aggrecan, laminin, versican, perlecan, fibronectin, and tenascin (10,11). High levels of MMP-1 have been reported in varicose veins (12). In spontaneously hypertensive rats, DeLano and Schmid-Schonbein showed that cell membrane receptor cleavage by MMP-1 was associated with insulin resistance (13). Elevated MMP-1 and -8 activity in the mesentery were observed in rat models of acute venous hypertension (12). In the same study, upstream of the venous pressure increased vascular endothelial growth factor receptor-2 (VEGRF2) expression was observed, and became more elevated with MMP inhibition (12). In human carotid atheroma, angiotensin II receptor 1 blockage significantly reduced MMP-1 and -8 concentrations within atheroma suggesting the involvement of these




Figure 1. Schematic of generalized structure of MMPs. The Prodomain has a cleavage site at RxRRR which activates the subsequent autocatalysis of the pro-enzyme. Although MMP-23 has the cleavage site, it is the only one that lacks a prodomain. The catalytic domain is common across all MMPs consisting of two Zn^{2+} ions where one is purely structural, while the other is involved in catalytic activity. The catalytic zinc interacts with a cysteine residue (cysteine switch) within the prodomain to remain inactive. The Hemopexin-like domain and catalytic domain are connect by a linker peptide, and is observed at the C-terminus of all MMPs except for MMP-7,-23, and -26. Its sequence homology resembles that of hemopexin, a protein with heme-binding capabilities. It enhances substrate recognition and specificity in stromelysins and collagenases, but not required for elastase activity in metalloelastase. Lastly, TIMP: proenzyme interactions are facilitated by this domain in gelatinases. The Fib1-3s are fibronectin-like type II domains found only in gelatinases.

MMPs in plaque stability (14). Recent findings suggest that M1 macrophage-mediated MMP-13 expression induced neointima formation after vascular injury in eNOS knockout mice, and that MMP-13 is involved in vascular disease (15). Protease-activated receptor-1 (PAR1) is a G protein-coupled receptor and MMP-13 has been demonstrated to cleave PAR1 resulting in the activation of G-protein signaling pathway in restenosis and atherothrombotic diseases (16). In addition, MMP-13 is an interstitial collagenase and has been shown to have significant renal expression related to ECM remodeling during progressive renal diseases (17,18). In a recent study, we reported that increased expression of MMP-13 in mouse glomerular ECs were mediated by homocysteine, a non-protein amino acid and vascular risk factor (19). Using pharmacological MMP-13 inhibitor, Quillard *et al* showed that the accumulation of collagen in the plaque is associated with resistance to rupture (20).

Although the expression of MMP-18 has been reported in a variety of human cell lines, it has not been associated with any disease (21,22).

5.2. Gelatinases

MMP-2 and MMP-9 are gelatinases highly expressed in varicose veins (9). Increased MMP-9 activity has been demonstrated in the mesenteric veins of acutely hypertensive rats (12). In a meta-analysis focusing on characterizing the expression profile of low grade inflammation in patients with coronary artery disease, MMP-9 levels were found to be elevated suggesting its use as a potential biomarker, however, further studies are required to conclude the causality of low grade inflammation in vascular diseases (23).

The receptor activation of NF- κ B was studied by using receptor activator of nuclear factor kappa-B




Figure 2. Subgroup classification of MMPs.

ligand (RANKL) /Osteoprotegerin ratio in a cohort study consisting of patients with severe carotid artery stenosis and was observed to correlate directly with MMP-9 activity (24). Hydroxytyrol is commonly found in olive oil and is associated with cardioprotection. It has been suggested that this molecule inhibits monocyte activation of cyclooxygenase 2 which generates eicosanoids capable of suppressing MMP-9 activity (25). The proposed mechanism of action is inhibition of the protein kinase C alpha and beta 1 pathways conferring anti-atherosclerotic and anti-inflammatory properties (25). High serum MMP-9 is associated with increased intimal thickness and plaque instability (26). Tumor necrosis factor-induced activation of eNOS along with MMP-9 and protein kinase B activation are markers for endothelial dysfunction which is mitigated by treatment with apigenin, an estrogen receptor agonist (27). The formation of calcified aortic valve is influenced by a number of cardiac risk factors, molecular signaling pathways, and hemodynamics (28,29). A model for fluid shear stress (FSS) showed increased ECM degradation due to elevated MMP-9 and MMP-2 activity was associated with FSS (30). In patients suffering from cardiac disease, increased expression and binding of CD40 ligand/receptor has been associated with activation of MMP-9 and pro-angiogenesis (31). The upregulation of soluble CD40 ligand (sCD40L) occurs via CD40/CD40L/ TRAF axis and the stimulation of sCD40L has been shown to induce the phosphorylation of p38 MAPK and to increase the release of MMP-9 in endothelial progenitor cells (31). In a recent study, vitamin C deficiency directly correlated with stress-induced cardiac damage which was associated with increased activity of MMP-2 and -9 (32).

The cardiac matrix was shown to regulate physiological processes involved in angiogenesis, hypertrophy, and cardiac fibrosis through the differential microRNA profile (33). A recent review article reports the current mechanistic understanding on the effects of reactive oxygen/nitrogen species effect on MMP-2 expression (34).

MMP-2 was also shown to induce VSM relaxation in the inferior vena cava of rats leading to venous dilatation, varicose veins and insufficiency (35). Treatment with L-NG-nitroarginine methyl ester (L-NAME) and indomethacin showed that elevated levels of nitric oxide (NO) or prostacyclin was not involved because inhibition of nitric oxide synthase (NOS) and cyclooxygenase did not stop vascular smooth muscle (VSM) relaxation (8,35). Iberitoxin treatment was successful in stopping VSM relaxation through the action of blocking large conductance Ca^{2+} -activated K^{+} channels, suggesting a role in the VSM hyperpolarization pathway (8).

In patients with chronic ischemic stroke it has been demonstrated that decreased plasma concentrations of MMP-2 and homocysteine were more closely associated with intracranial atherosclerosis (ICAS) than extracranial atherosclerosis (ECAS) suggesting that MMP-2 may play a role in the development of ICAS (36). In another clinical study, Shimizu *et al* reported the progression of intracranial large artery atherosclerosis (ILA) in 12.5% patients with acute ischemic stroke, and these patients exhibited decreased MMP-2 and increased MMP-9 along with increased IL-6 in their serum (37). Although the authors did not conclude on

Table 1. MMPs in vascular health and disease

Type	Enzyme	Other name (s)	Associated vascular events (Ref.)
Collagenases	MMP-1	Interstitial collagenase Fibroblast collagenase	Venus hypertension (10) Carotid atheroma (14) Insulin resistance (13)
	MMP-8	Neutrophil collagenase	Carotid atheroma (14)
	MMP-13	CLG3; MANDP1; Collagenase-3	Neointima formation (198) Restenosis/atherothrombosis (16) Renal Disease (17, 18)
	MMP-18	Collagenase-4 Xenopus collagenase	Not known
Gelatinases	MMP-2	Gelatinase A	ICAS, thrombosis, heart and renal disease (12,36,39,197)
	MMP-9	Gelatinase B	Hypertension (12) Carotid stenosis (25) Cardiac and renal disease (31,197)
Stromelysins	MMP-3	Stromelysin-1	Inflammatory bowel disease (44)
	MMP-10	Stromelysin-2	Inflammatory bowel disease (44) Tumor growth and progression (46) Microvascular disease in diabetes (47) Muscular dystrophy (48)
	MMP-11	Stromelysin-3	Mammary gland development (49)
Membrane type	MMP-14	MT1-MMP	Lung tumor (51) Neuroinflammation (53) Neointima formation (54) Pressure overload (59) Macular degeneration (64) Hypertension (66)
	MMP-15	MT2-MMP	Inflammatory disease (71)
	MMP-16	MT3-MMP	HSP and deep vein thrombosis (72,73)
	MMP-17	MT4-MMP	Tumor growth and metastasis (74)
	MMP-24	MT5-MMP	Deep vein thrombosis (73)
	MMP-25	MT6-MMP	Abdominal aortic aneurysm (75)
Matrilysins	MMP-7	PUMP1	Myocardial infarction (77) Kawasaki disease (80) Coronary artery disease (81) Hypertension (83,87)
	MMP-26	Matrilysin-2 Endometase	Wound healing (88) cerebral amyloid angiopathy (90)
Enamelysin	MMP-20	Enamel metalloproteinase	No report
Metalloelastase	MMP-12	Macrophage metallo-/elastase (MME or ME)	Atherosclerosis (92,99) Aortic dissection (96) Retinopathy (101) Intracerebral hemorrhage (102) Peripheral vascular damage (104) COPD (108) Deep vein thrombosis (73)
Unclassified	MMP-19	RASI-1	Thoracic aortic aneurysms (110) Cerebral amyloid angiopathy (90) Rheumatoid arthritis (112)

contd...

Table 1. (Continued)

Type	Enzyme	Other name (s)	Associated vascular events (Ref.)
	MMP-21	Xenopus MMP (XMMP)	Melanoma development (113) Tissue remodeling/embryogenesis (114,115,117)
	MMP-23	MMP-23A/B	Thrombosis (73) Reproductive system (11)
	MMP-27	Epilysin	Not known
	MMP-28	Epilysin	Left ventricular remodeling (125) Soft tissue edema (72)

Abbreviations: CLG3, collagenase-3; MANDP1, Metaphyseal anadysplasia 1; ICAS, Intracranial atherosclerosis; HSP, Henoch–Schoenlein purpura; COPD, Chronic Obstructive Pulmonary Disease

the role of MMPs in this study, it is possible that both MMPs may have role in ILA progression along with IL-6. It is also known that carotid artery atherosclerotic plaque rupture can lead to thromboembolism and stroke. In fact, Heo *et al* conducted a study to determine the relationship between the expression of MMP-2 and -9 in patients with atherosclerotic plaque instability. Their findings demonstrated a significant correlation between increased expression of MMP-2 and -9 and cap rupture suggesting their involvement in plaque instability (38).

Cell-to-cell gap junction proteins play a pivotal role in vascular remodeling and disease progression. In a pressure overload rodent model, our group demonstrated that gap junction proteins, connexins-37 and -43 were decreased in TIMP-2 knockout mice with ascending aortic banding (AB), a model of pressure overload-induced left ventricular dysfunction and heart failure (39). In addition, decreased expression of pro-angiogenic MMP-2, VEGF and increase in anti-angiogenic factors exacerbated abnormal left ventricular remodeling in these animals suggesting a possible relationship between MMP-2, connexins-37 and -43 in heart failure (39).

Unlike gap junction proteins, caveolae are lipid rafts within plasma membrane and contains caveolins which are involved in endocytosis, transcytosis and signal transduction in vascular health and disease. In bleomycin-induced caveolin-1 knockout mice, Shivshankar *et al* demonstrated that MMP-2 and -9 expression was reduced and this was associated with attenuated pulmonary injury and collagen deposition in caveolin-1 knockout mice (40). On the other hand, loss of caveolin-1 has been reported to upregulate MMP-2 and -9, tight junction proteins, and enhanced blood brain barrier (BBB) permeability in focal cerebral ischemia and reperfusion injury (41). These above experimental evidences suggest that gap junction proteins and collagenases (MMP-2 and -9) may have a role in BBB permeability as observed in caveolin-1 knockout mice where one modulates another and vice versa leading to vascular pathogenesis. Furthermore, our group has demonstrated that hyperhomocysteinemia enhanced

cerebrovascular permeability through activation of MMP-9 and increased the formation of fibrinogen- β -amyloid complex within the brain (42). Additionally, increased cerebrovascular permeability and memory loss was also observed with increased MMP-9 activity which was ameliorated by MMP-9 ablation (43).

5.3. Stromelysins

Stromelysin-1, -2, and -3 subcategorize MMP-3, MMP-10, and MMP-11 respectively. Among them, MMP-3 and -10 are intestinal proteases, and are established key players in the development of ulcers in inflammatory bowel disease (44). In addition, although in chronic human hypertension elevated activity of MMP-3 has been reported (45), MMP-10 experimentally has been shown to regulate tumor cell migration, invasion and EC tube formation (46). In a recent report, Toni *et al* documented that increased circulating MMP-10 was associated with increased microvascular disease risks including diabetic retinopathy in type 1 diabetes (47). In addition, MMP-10 has been reported to play a critical role in muscle regeneration during injury and muscular dystrophy (48). Using a MMP-11-deficient mice model, Tan *et al* showed that during postnatal mammary gland development ductal tree, alveolar structure and milk production were reduced suggesting a paracrine function of MMP-11 (49). MMP-11 is a negative regulator of adipogenesis which reduces and even reverts adipocyte differentiation, and has been shown to require correct collagen IV folding for fat tissue cohesion and adipocyte function (50).

5.4. Membrane-type MMPs

MMP-14, -15, -16, -17, -24 and -25 are membrane type or membrane bound enzymes. MMP-14 was the first MMP discovered possessing a transmembrane domain cloned from lung tumor cells conferring their invasiveness and metastasis (51). A study focusing on ischemia-reperfusion in the spinal cord injury of rats reported that TIMP-2 binding to MMP-2 activates MMP-14 (52). Furthermore, MMP-14 has been found to be involved in neuroinflammation (53). In another study, elevation of MMP-14 and MMP-2 correlated with abnormal aortic remodeling in sheep fetus development

under hypoxic conditions. Furthermore, aortic intimal proliferation was associated with increased expression of cell adhesion molecule, E-Selectin suggesting interaction between endothelial cells and leukocytes (54).

In diabetic retinopathy, MMP-14 induced MMP-2 activation has been associated MMP-2 interaction with integrin and promotion of apoptosis leading to impaired retinal pericyte survival (55). In an in vitro study using VSMCs, MMP-14 induced ApoE degradation was associated with migration of VSMCs in both lipid-free and lipid-loaded treatment (56). Further, proteomic studies has shown that ApoA1, a lipid-free lipoprotein is a substrate of MMP-14 and more susceptible to cleavage than the lipid-loaded lipoprotein suggesting that degradation of high-density lipoprotein (HDL) can severely hamper lipid metabolism and possibly induce vascular disease (57). In salt-sensitive rats, elevation of MMP-14 was seen in late phase of chronic hypertension and left ventricular remodeling (59).

The ischemia-reperfusion (IR) model was applied to the left rat lung, and showed upregulation of several MMPs, including MMP-2 and MMP-9. Uninhibited protease activity was observed during the early phase of reperfusion which was demonstrated to arise from plasma via protein extravasation instead of *de novo* synthesis within the pulmonary tissue. Preconditioning rats with NO was shown to mitigate protease activity suggesting the mitigation IR injury (58). In another study, IL-6 induced upregulation of MMP-14 has been reported to contribute in carotid artery plaque formation involving Raf-MEK-ERK1/2-AP-1 pathway leading to ECM collagen degradation (61). In group X secretory phospholipase A2-deficient double knockout mice treatment with angiotensin II failed to induce MMP-2, -13, -14 and was associated with decreased progression of abdominal aortic aneurysms in this model suggesting a pathogenic role for MMP-14 (62). Elevated MMP-14 has been observed in early phase venous thrombosis. However, its role in thrombus formation or resolution has not been defined (63). In age-related macular degeneration, MMP-14 and basigin mediated increase in MMP-2 activity was associated with ECM dysregulation and sub-retinal pigment epithelium deposits (64).

MMP-14 has been shown to cleave brain-specific angiogenic inhibitor-1 to yield vasculostatin-40 a potent angiogenesis inhibitor (65). Early stage hypertension is associated with increased MMP activities including MMP-14 and enhanced NADPH oxidase activity suggesting that tissue remodeling occurs from the onset of hypertension and is linked to oxidative stress (66). This study further suggests that vascular remodeling associated with the early phase of hypertension may be mitigated through the administration of MMP inhibitors or antioxidants (66).

In hepatic ischemia reperfusion injury (IRI), fibronectin- $\alpha 4\beta 1$ integrin interaction with macrophages leads to increased MMP-9 and -14 levels worsening the injury (67). Using a peptide, connecting segment-1, CS-1 the authors showed that the levels of both MMPs decreased offering protection to the liver (67). Furthermore, the pharmacological inhibition of p38 MAPK pathway via SB203590 also mitigated the MMP-14 expression suggesting the involvement of this pathway in hepatic IRI (67).

In tumor pathology, angiostatin mediated inhibition of angiogenesis was found to be dependent on MMP-2 and MMP-14 expression (68). This was associated with an increase in hypoxia-induced VEGF which was sufficient in protecting against angiostatin-induced apoptosis (68).

In another study, osteopontin upregulation directly correlated with MMP-14 expression in a rat model of balloon-injured carotid artery suggesting a pathogenic role. One study showed that MMP-14 expression levels increased with respect to osteopontin upregulation in balloon-injured rat carotid arteries suggesting that osteopontin may be involved in the signaling leading to MMP-14 expression (69). The study suggested that osteopontin may be a potential target for avoiding arterial restenosis (69). Sirtuin-1, deficiency in mice was shown to decrease MMP-14 expression promoting a fibrotic phenotype which was associated with vascular dysfunction and diminished angiogenesis (70).

There is limited literature on the role of MMP-15 in vascular diseases. One study reported the upregulation of MMP-15 in chronic inflammatory diseases and malignant tumors (71). It is reported that VEGF-A upregulates ADAMTS-1 (a Disintegrin And Metalloproteinase with Thrombospondin motifs-1) and increases the development of large 'mother' vessels in human cancers (71). In the above study, VEGF-A was found to upregulate MMP-15 and ADAMTS-1 which together contributed to pathological angiogenesis (71).

MMP-16 levels were reported to be upregulated in patients with Henoch-Schönlein purpura (72). Another study focusing on the MMP expression profile in traumatic deep vein thrombosis (TDVT) in rats reported low expression of MMP-16 and -24 in early thrombotic stage but was upregulated during the resolution stage (73). The role of MMP-17 in vascular disease has not been described so far, however, it has been reported to stimulate tumor growth and facilitate a permissive microenvironment for metastasis (74).

MMP-25 expression was shown to be downregulated in the aortic wall of patients suffering from abdominal aortic aneurysm after the administration

of doxycycline (75). Furthermore, increased MMP-25 expression was observed in classically activated macrophages, and increased mRNA expression was observed in alternate activation of macrophages (76).

5.5. Matrilysins

MMPs-7 and -26 are matrilysins. MMP-7 has been shown to be involved in adverse left ventricular remodeling post-myocardial infarction and proteomic analysis revealed fibronectin and tenascin-C as its substrate (77). Thyroid cancer-1 gene was suggested to activate MMP-7 and endothelial growth factor downstream of the Wnt/ β -catenin signaling pathway to enhance non-small-cell lung cancer in patient (79).

In patients with Kawasaki's disease, increased expression of integrins α 4 and α M on macrophages and myofibroblasts were associated with increased MMP-7 activation and collagen type 1 α 1 expression in coronary artery stenosis (80).

In another study involving coronary artery disease patients, the expression of MMP-7, osteopontin, IFN-gamma, and osteopontin were found to be increased suggesting its potential use as biomarkers (81). MMP-7 has been reported to be increased by over 100-fold in patients with atherosclerotic carotid plaques and associated with plaque instability (82). In addition the upregulation of MMP-7 correlated with overexpression of inflammatory genes, RANKL and CD68 (82). In spontaneously hypertensive rats, the increase in MMP-7, -9 and elastase expressions has been demonstrated to cleave ICAM-1 in the glomeruli leading to renal inflammation (83). Using a protease-activated receptor 1 antagonist, F16688, Chieng-Yane et al demonstrated that downregulation of MMP-7 and TNF- α levels mitigated post angioplasty restenosis of carotid artery in rats (84). Similarly, using RNA interference against MMP-7 and TACE, Odenbach et al demonstrated mitigation of MMP-2 mediated angiotensin-II-induced cardiac pathology (85). Taken together, the above studies suggest a significant role for MMP-7 in various vascular pathologies. It is known that β_2 adrenergic receptor (β_2 AR) agonists mediate vasodilatation of blood vessels (87). In rats, when MMP-7 and -9 were injected into the superior mesenteric artery the diameter of arterioles and venules in the mesentery were reduced and these effects have been attributed to MMP-7 and -9 mediated cleavage of β_2 AR (87).

A study focusing on endothelium regeneration post-vascular injury reported a decrease loss of pertussis toxin-induced endothelial derived relaxation factor mechanisms as well as an increase in MMP-7 expression (86).

In wound healing, MMP-26 expression is associated with chronic wound healing (88). In an *in vitro* study using human macrophages,

Krishnatry et al observed that acute nitroglycerin exposure decreased MMP-26 expression along with testican-1, integrin α -1, thrombospondin-3, fibronectin-1 suggesting that nitroglycerin modulates ECM by changes in the activities of proteases (89). Furthermore, MMP-26 was found to be associated in patients with cerebral amyloid angiopathy (90).

5.6. Enamelysin

MMP-20 is a protease secreted during teeth development and functions mainly in the deposition of minerals in the dental matrix. There is not reported literature on its vascular effects.

5.7. Metalloelastase

MMP-12 is a metalloelastase originally discovered in alveolar macrophages of cigarette smokers (91). In a mouse model of brachicephalic artery atherosclerosis, MMP-12 was found to be detrimental to plaque stability (230). Using a MMP-12 inhibitor, RXP470.1, Johnson et al demonstrated a significant reduction in plaque formation, necrosis, calcification and macrophage apoptosis. Furthermore, this was associated with increased smooth muscle cell: macrophage ratio leading to a loss of thickness of fibrous plaque and slowing of atherosclerosis (92).

Henoch-Schönlein purpura (HSP) is a IgA mediated immune complex disease characterized by small vessel vasculitis of the skin, gastrointestinal tract, kidneys, joints and rarely the respiratory and central nervous system. Increased MMP activity has been implicated in the pathogenesis of HSP (93). In a recent study, patients with HSP receiving steroids showed negative correlation of MMP-12 suggesting a role of this MMP-12 in HSP (72). Further, a recent study identified MMP-12 as a potential biomarker in patients with Stanford-A Acute Aortic Dissection (94). In a mice model of angiotensin-II induced abdominal aortic aneurysm, 3, 4-Benzopyrene, a compound present in cigarette was found to increase macrophage infiltration, upregulation of MMP-2, -9 and -12 and apoptosis of vascular smooth muscle cells (95). Further, MMP-12 levels were found to be elevated in patients with aortic dissection and coronary artery disease suggesting its use as a potential biomarker and effect of treatment (96).

In patients with abdominal aortic aneurysm (AAA), elevated leptin, a hormone involved in ECM degradation was associated with increased MMP-12 (97). Further, when ApoE $^{-/-}$ mice were treated with local leptin, the expression of MMP-12 and MMP-9 increased by several fold which was associated with medial degeneration of aorta suggesting a link between leptin and AAA (97). MMP-12 ApoE $^{-/-}$ mice increased levels of MMP-12 and exacerbated degeneration of the aortic wall in Ang-II-induced abdominal aortic aneurysm was detected which further demonstrated enhanced degeneration upon endogenous leptin induction (97).

Osteopontin, an atherosclerotic factor, can be cleaved by MMP-12 into an N-terminal and C-terminal fragment where the former is associated with high-risk carotid plaque formation in hypertensive patients (98). In another clinical study carotid atherosclerotic plaques were found to be associated with MMP-12-expressing foam cells and increased MMP-12 is linked to plaque instability (99,100).

Using MMP-12 knockout mice, Li et al demonstrated decreased macrophage infiltration in oxygen-induced retinopathy (101). Furthermore, it reduced adverse neovascularization and promoted nonpathological revascularization of the retina (101). Increased MMP-12 has been associated with disruption of blood brain barrier following intracerebral hemorrhage (102). Furthermore, in a neonatal hypoxic-ischemic brain injury, increased MMP-12 expression was observed in neurons suggesting its participation in immature brain injury (103).

Elevated MMP-12 was observed in systemic sclerosis patients and associated with the classical symptoms of scleroderma including peripheral vascular damage (104). Aortic dilation induced by congenital bicuspid aortic valves is associated with increased MMP-12 levels among other MMP and TIMP levels (105). Spleen tyrosine kinase leads to JNK and p38 signaling leading to glomerular injury which enhances pro-inflammatory expression of MMP-12 (106). Certain MMP-12 haplotype are associated with elevated risk of aneurysm in patients suffering from Kawasaki disease (107). Mice susceptible to atherosclerosis showed cigarette smoke-induced COPD vascular effects as well as increased activity of MMP-12 (108). Furthermore, pentraxin-3, a modulator of inflammation, was upregulated upon cigarette smoke as well as an increase in MMP-12/TIMP-1 ratio (109). Expression of MMP-12 was found to be elevated in deep vein thrombosis in rats (73).

5.8. Unclassified MMPs

Some MMPs such as, MMPs-19, -21, -23, -27 and -28 remain uncategorized. In patients with tricuspid aortic valves, elevated MMP-19 has been associated with thoracic aortic aneurysms (110). Furthermore, a human study has revealed immunoreactivity against MMP-12 in cerebral blood vessels in cerebral amyloid angiopathy (90). A study focusing on the acute and chronic manifestations of myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalitis in mice showed that VEGF levels directly correlated with demyelination of lesions which was associated with increased MMP-19 (111). MMP-19 has been extracted from the synovium of patient suffering from rheumatoid arthritis and was found to be localized to smooth muscle cells in the media of blood vessels (112).

Since its original description in ovarian serous tumors, the role of MMP-21 has now expanded to include

invasiveness in breast cancer cells and early melanoma development (113). Apart from tumor progression, MMP-21 activity is associated with embryogenesis (114,115,117). Also, MMP-21 may be a marker for keratinocytes as demonstrated by a study which showed increased MMP-21 upon keratinocyte differentiation in cell culture (116). Increased MMP-21 expression was suggested to play a role in invasiveness of human colorectal cancer and progression in human gastric cancer (118, 119).

MMP-23 is encoded by two genes, MMP23A and MMP23B (120, 121). MMP23A is a pseudogene which is duplicated on chromosomal region 1p36.3, while MMP23B is the protein encoding gene. In a study involving DVT in rats, the expression of MMP-12 was found to be low during thrombus formation but increased during resolution suggesting a wound healing role than pathological (73). MMP-23 expression has been described in reproductive tissues such as, testis, prostate and ovaries however, their exact role remains unknown (11).

MMP-27 was first discovered as epilysin expressed in response to injury, and in testis and keratinocytes (122). The role of MMP-27 in vascular disease has currently not been identified. MMP-27 is expressed in B-cells, bone and kidney tissues of rats (123). In humans, MMP-27 has been implicated in osteogenesis (231). Although mutations in MMP-27 have been identified in thyroid cancers, it has not been suggested to play a role in tumorigenesis (124).

The role of MMP-28 in vascular diseases is yet to be defined. However, in a recent study MMP-28-deficient mice worsened left ventricular remodeling to the point of rupture as a result of inhibiting the type 2 subpopulation of macrophages (125). In a clinical study focusing of MMP/TIMP profile in children with Henoch-Schönlein purpura, decreased MMP-28 expression was observed in soft tissue edema and the levels of MMP-19 was decreased during convalescent stage compared to its level in the acute stage (72). Treatment with steroid mitigated the changes in MMP and TIMP expression in these patients (72).

6. REGULATION OF MMPs IN VASCULAR DISEASES

MMP expression and their biological function are regulated by a variety of factors that include biological effectors, endogenous inhibitors, epigenetic regulators, miRNAs and pharmacological agents. A summarized chart is presented in Table 2. Below, we discuss how these factors regulate MMPs in normal and pathophysiological conditions.

6.1. Biological activators of MMPs

Oxysterols, a promotor of oxidative stress through Nox2 activation, has been shown to enhance the

Table 2. Regulators of MMPs and examples of their targets

Category	Type	Class	Name	Target MMPs (Ref.)
Biological	Activator	Oxidized derivatives of cholesterol	Oxysterols	MMP-9 (126)
	Inducer	Transcription factor	E2F1	MMP-9, -16 (127)
Natural	Inhibitor	TIMPs	TIMP-1	MMP-8, -9 (135,144)
			TIMP-2	MMP-2, -14 (199-201)
			TIMP-3	MMP-9 (202)
			TIMP-4	MMP-2, -9 (139-143)
Epigenetic	Modulator	Methylation	Dystrophin	MMP-2 (150)
miRNAs	Gene regulator	-	-	MMP-2, -9, -11, -13 (158,162,164-167,169)
Pharmacological	Inhibitor	Anti-cancer drug	Batimastat	MMP-2, -14 (203-205)
			Marimastat	MMP-1, -2, -3, -7, -9 (172,206)
			Ilomastat	MMP-2, -9 (207, 208)
			Cipemastat	MMP-2, -9 (205)
	Inhibitor	Statins (cholesterol lowering drug)	Cerivastatin	MMP-1, -2, -3, -9 (209-211)
			Simvastatin	MMP-1, -3, -9 (209,212-216)
			Lovastatin	MMP-1, -3, -9 (209,216)
			Fluvastatin	MMP-9 (217-219)
	Inhibitor	Hydroxamates	R-phosphonate	MMP-8 (220)
			Sulfone hydroxamates	MMP-1, -2, -9, 13 (221)
	Inhibitor	Sulfa drugs	Sulphonamides	MMP-8, -12, -13 (222)
Unclassified	Inhibitor	Recombinant	C-TIMP-2	MMP-2 (182)
	Inhibitor	Pyrimidine	5-hydroxy, 5-substitute-pyrimidine-2,4,6,-triones	MMP-2, -9 (183)
	Inhibitor	Methyl rosmarinate derivatives	(R)-10n	MMP-1 (223)
	Inhibitor	Divalent cation chelators	Alendronate and EDTA	MMP-1, -3, -9, -13 (187,224)
		Quinolinone-derivative	Cilostazol	MMP-1, -9 (188,225-227)
	Inhibitor	Anti-hypertension drug	Captopril	MMP-2, -9 (189,190)
			Candesartan	MMP-9 (191)
	Inhibitor	Herbal	Hydroxysafflor yellow A	MMP-2, -9 (193)
	Inhibitor	Flavonoid	Kaempferol	MMP-2 (194)
	Inhibitor	Gasotransmitter	Hydrogen sulfide	MMP-2, -9 (195-197)
	Inhibitor	Phosphinic peptide	RXP470.1	MMP-1, -2,-3,-8,-9, -10,-12, -13, -14 (228)
			RXP470, Compound 4	MMP-1, -2, -3,-7, -8, -9, -10, -12, -13, -14 (229)

Abbreviations: R-phosphonate, (1-(4'-methoxybiphenyl-4-sulfonylamino)-2-methylpropyl) phosphonate; EDTA, Ethylenediaminetetraacetic acid.

effects of MMP-9 (126). On the other hand, E2F1 is a transcription factor that modulates cell cycle regulation, proliferation and apoptosis, and has shown to enhance MMP expression (127).

6.2. Natural inhibitors of MMPs: tissue inhibitor of metalloproteinases (TIMPs)

A number of inhibitors for MMPs have been described over the years. The most common include

endogenous inhibitors known as TIMPs. This family consists of four protease inhibitors TIMP 1-4 which exist as glycosylated or unglycosylated form. TIMPs are 21 to 29 kDa protein consisting of an N-terminal oligosaccharide/oligonucleotide binding (OB)-fold of ~125 amino acids, 5 beta-barrels, and a C-terminal portion ~60 amino acids long forming a beta-turn (128-130). The N-terminal domain interacts strongly with the catalytic domains of MMPs (129). In some cases, however, the C-terminal domain can further enhance the MMP/TIMP interaction (131). Furthermore, TIMPs can also interact to form complexes with pro-gelatinases suggesting that the C-terminal domain interacts with the hemopexin-like domain (131).

TIMP-2: proMMP-2 complex has an important role in both activation and inhibition of MMP-2 (132). A ternary model for TIMP-2: proMMP-2 interacting with MT1-MMP has been proposed (2). Thus, studying MMP/TIMP ratios enable to define the collective role of TIMPs in vascular disease. A time course study performed in rats demonstrated that besides the expression of MMP-9 protein and mRNA the MMP-9: TIMP-1 ratio correlated with brain water content (BWC) following acute cerebral infarction (133). TIMP-1 concentration alone did not correlate BWC in this cerebral edema model suggesting that there was no disenable relationship between TIMP-1 concentration and edema (133).

An epidemiology study concluded that certain polymorphism within the promoter regions of MMP-9 and TIMP-2 is statistically associated with varicose vein development within a subset of the Chinese population (134). In another study focusing on obesity increased plasma concentrations of MMP-9 and MMP-9: TIMP-1 ratio and MMP-8 and MMP-8: TIMP-1 ratio was observed in obese women versus lean women suggesting their association with obesity (135). In addition, MMP-9 levels and MMP-9:TIMP-1 ratio was associated with healing in diabetic foot ulcers (136). However, there was only a slight variation in TIMP-1, TIMP-2, and MMP-2 when comparing good vs. poor healing outcomes (136).

TIMP-1 has been used in gene therapy by viral and plasmid delivery systems. Hybridization of TIMP-1 to urokinase receptor decreased neointimal formation in vein cultures (137). Furthermore, in an *in vivo* model of venous graft interposition to carotid artery, TIMP-1 urokinase protein reduced graft thickening suggesting its potential as a therapeutic agent (138). TIMP-4 was shown to mitigate MMP-2 expression in an ischemia-reperfusion injury rat model of myocardial infarction (139). In addition, monocytes isolated from abdominal aortic aneurysm (AAA) were shown to have a greater capacity for transmigration and EC adhesion along with increased MMP-9 and decreased TIMP-4 levels (140). Furthermore, intermittent hypobaric hypoxia has been shown to ameliorate the effects of

ischemia-reperfusion by decreasing MMP-2 activation, and increasing TIMP-4 (141).

A study focusing on ataxia telangiectasia, mutated heterozygous kinase knockout (ATM hKO) mice showed decreased levels of TIMP-4 within the infarct tissue which was associated with increased MMP-9 expression and fibrosis (142). In another study, fibrinogen induced caveolae formation as well as caveolin protein 1 expression, and its phosphorylation was mitigated in presence of the TIMP-4 and MMP-9 modulation (143).

Sirtuin1 (SIRT1) is a protein/histone deacetylase known for its protective effects against development of pulmonary emphysema in smokers (144). In a study by Yao et al, SIRT1 deficiency was associated with decreased TIMP-1 and increased MMP-9 activity in human subjects suffering from COPD and in the lungs of mice exposed to cigarette smoke, whereas increased SIRT1 in transgenic mice was associated with decreased MMP-9 activity (144). The above study did not demonstrate changes in the levels of MMP-2, -12 and TIMP-2, -3 or -4 were observed (144). Additionally, in an *in vitro* rat cardiac fibroblast model, El Hajj et al demonstrated that ethanol exposure up-regulated TIMP-1, -3, and -4 levels with no significant changes in MMP profile (145). They concluded that MMP/TIMP imbalance favors collagen accumulation in the development of myocardial fibrosis and cardiac dysfunction in chronic alcohol abuse (145).

6.3. Epigenetic regulation of MMPs

Epigenetics is defined as reversible events and consists of gene silencing mechanisms which stabilize gene expression without modifying the DNA sequence. In mammalian cells, the major epigenetic mechanism includes, DNA methylation, histone modification, and small non-coding RNA (146). DNA methylation is carried out by three DNA methyltransferases (DNMT): DNMT 1, DNMT3, and DNMT 3b. Although epigenetic regulation of MMPs have not been extensively studied in vascular diseases much of what is known has been uncovered through cancer research. Several cancers have overlapping vascular pathology which we discuss in the following paragraphs. In a recent study, methylation of cytosine within the promoter region of dystrophin was examined by using Duchenne muscular dystrophy (DMD) knockout mice, and this deficiency was shown to increase MMP-2 expression levels (150). In breast cancer cells MD-MB-231, high glucose led to the phosphorylation of histone 3 at the Ser10 residue while dephosphorylating the Ser9 residue (151). This event correlated with the increase in DNMT1 expression (151). Silencing GSK-3 β by siRNA inhibited the phosphorylation of H3, and thus decreasing DNMT1 expression (151). Furthermore, phospho-H3 levels were directly correlated with MMP-7 expression (151).

MMP-14 was suggested to be a regulator of H3K9ac in adipogenic collagenolysis (152). Another

study suggested that proMMP-1 expression is influenced by epigenetics in human fibrosarcoma cells even though its promoter is not believed to possess CpG islands, yet proMMP-1 expression increased under 5-aza-dC treatment which was mitigated with cycloheximide suggesting epigenetic regulation through some other intermediate product (153). Enzymes involved in the pathology, mainly MMP-9 and superoxide dismutase 2, of diabetic retinopathy have been reported to be under the epigenetic regulation of histone lysine demethylase 1, (LSD1) and DNMT (154). Our lab has recently demonstrated that changes in the levels of MMP-9, TIMP-1 are regulated by DNMT1, 3a, Methyl CpG-Binding Domain Protein 2 (MBD2), and H3K9 contributing to aortic remodeling during hyperhomocysteinemia (156).

The expression of MMP9 is inhibited by trichostatin A (TSA), a HDAC inhibitor, by its action on thrombospondin-1 (TSP-1), an adhesive glycoprotein (147,148). TSP-1 stabilizes the ECM and also suppresses VEGF release thus regulating angiogenesis (148).

Proto-oncogene c-Fos was also shown to be linked to MMP-2/MMP-9 expression (160). Treatment of cells with OxLDL caused c-Fos activation to decreased histone deacetylase 1 (HDAC1) expression levels (160). Also, shRNA-mediated knockdown of c-Fos restored HDAC1 mRNA and protein expression (160). The increased acetylation and decreased methylation of H3K9 had disappeared in the knockdown of c-Fos treated with OxLDL suggesting that c-Fos was necessary for histone modification and lead to MMP-2/MMP-9 overexpression further downstream of the signaling pathway (160). Furthermore, since c-Fos can activate transcription factor AP-1, a link between OxLDL, AP-1, miRNA-29b, and cardiovascular disease had been suggested (160). MMP-9 has also been shown to be regulated epigenetically (161).

6.4. miRNA regulation of MMPs

MicroRNAs (miRs) are small non-coding RNAs which regulate transcriptional and post-transcriptional gene expression (157). MicroRNA-29b (miRNA-29b) has been shown to be an epigenetic regulator of pro-atherogenic genes (158). OxLDL was shown to up-regulate miRNA-29b expression in a dose-dependent and time-dependent manner within human aortic smooth muscle cells (HASMCs) (158). *In vivo* studies suggest that increased miRNA-29b levels reduced the expression of DNA methyltransferase 3b in primary human aortic smooth muscle cells, and subsequently lead to reduced MMP-2/MMP-9 silencing (158). These results suggested a mechanism for OxLDL to induce HASMC migration via miRNA-29b/DNMT 3b/MMP-2 and MMP-9 pathway (158). These findings reveal that miRNA-29b may generate atherosclerosis (158). Furthermore,

increased miRNA-29b levels were shown to dysregulate ECM homeostasis by impacting the expression of collagen (Col1A1 & Col3A1), and elastin (159).

Among miRs, miR133a, miR133b, and miR145 target SP-1 transcription factor which in turn decreases MMP-9 expression in renal cancer (162). In oral squamous cell carcinoma, miR2 targeted STAT3 which in turn decreased MMP-2 in WP1066 treated cells (163). Propofol administration was shown to induce miR-143 which targeted MMP-13 in an osteosarcoma cell line (164). This was shown to inhibit the cell proliferation and invasion which facilitated apoptosis (164). Moreover, miR-143 levels indirectly correlated with MMP-13 levels, which were restored with the application of anti-miR-143 (164). Under hypoxic conditions, neovascularization and therefore MMP-9 and VEGF were suggested to be under the control of miR-126 in monkey chorioretinal vessel ECs (RF/6A) (165). The miR21 expression was suggested to be induced by Ang II which induced MMP-2 expression in mouse cardiofibroblasts (166). TNF- α signaling leading to IL-6, iNOS, and MMP-9 expression and endothelial dysfunction was suggested to occur when miR-149 was down-regulated in a p38MAPK-dependent manner (167). MMP-14 was suggested to be downregulated by miR-9 expression (168). Finally, miR-98 is reported to inhibit tumor angiogenesis and invasion in part by targeting MMP-11 (169).

6.5. Pharmacological inhibitors of MMPs

Pharmacological inhibitors of MMP fit into two classes: non-specific and specific. The non-specific inhibitors act by chelating the catalytic Zn²⁺ ion (170,171). These inhibitors include but are not limited to batimastat, marimastat, ilomastat, PD-166793, and ONO-4817 (172,173). Peptide inhibitors containing motifs HWGF, CRRHWGFEFC and CTHWGF TLC provide targeted inhibition of MMP-2 and MMP-9 (174). Antibiotics have also demonstrated the ability to inhibit MMPs, such as the tetracycline class (175). Furthermore, chemically modified tetracyclines maintain MMP inhibition in the absence of antimicrobial activity (33).

Statins are a class of drugs used to lower cholesterol levels and have been shown to inhibit MMP-2, MMP-7, and MMP-9 (11). Although cerivastatin was withdrawn from the market due to cases of muscle breakdown, it has exhibited dose-dependent inhibition properties for MMP-1, MMP-3, and MMP-9 secretion in human VSMC (176). Lovastatin inhibited the inducible activity of MMP-1, -3 and -9, while it blocked the MMP-2 constituent activity in rabbit SMC whereas, TIMP-1 and -2 secretions remained uninhibited (176). Both cerivastatin and lovastatin inhibited the secretion of MMP-1, -3, and -9 in rabbit foam cells with cerivastatin demonstrating greater inhibition (176). In a study, aortic mRNA expression demonstrated elevated levels of MMP-1, MMP-9, and MMP-12 in rabbits that were fed

a high cholesterol diet which was decreased but not normalized upon fluvastatin treatment (177). Although MMP-2 level remained the same for normal diet, and cholesterol diet with or without fluvastatin, MMP-12 showed a pronounced decrease with fluvastatin treatment (177).

Interestingly, a recent study focused on a series of MMP inhibitors known as α -sulfone hydroxamates which were conjugated to various dyes for visualizing cells that express MMPs for as a way to measure their synthesis and potency in disease conditions (178). In particular, N-O-Isopropyl sulfonamido-based hydroxamates have shown to be selective inhibitors of MMP-12 and -13 (179,180).

Sulphonamides are another class of inhibitors which have been shown to inhibit MMP activity *in vitro* (181). However, their inhibitory effect *in vivo* remains known as it may be dependent on intracellular signaling and cross-talk between different compounds (181).

In order for proMMP-2 to become activated, the hemopexin domain has to interact with the C-terminal domain of TIMP-2 (182). Using recombinant technology, the activation of proMMP-2 was successfully blocked by TIMP-2 (C-TIMP-2) (182). The C-TIMP-2 was shown to interact with the inactive MMP-2^{E404A} and hemopexin domain of MMP-2 in a dose-dependent manner (182). Furthermore, C-TIMP-2 was shown to compete with TIMP-2 in its interaction with proMMP-2 (182). 5-hydroxy,5-substitute-pyrimidine-2,4,6,-triones demonstrate high potency in their IC₅₀ values for gelatinases (183). Also, 5-hydroxy moiety may enhance the pharmacokinetics of this inhibitor (183).

A new class of inhibitors has been identified with the ability to selectively inhibit MMP-13 (184). This class of pharmacological inhibitors is unique because they are non-zinc chelating (184). The structure-activity relationships (SAR) studies on this lead compound revealed that reducing the lipophilic property conferred metabolic stability, and lowered clearance rate *in vivo* (185).

Methyl rosmarinate derivatives have also been identified as a potential class of inhibitors for MMP-1 (186). A molecular scaffold has been identified and tested with SAR studies identifying potential lead compounds with IC₅₀ on micro molar scale (186). Alendronate and EDTA, divalent chelators, have been shown to inhibit MMP-9 activity irreversibly via plasmin-mediated inactivation (187). Cryptic plasmin degradation sites within the catalytic domain of MMP-9 become accessible to form hemopexin-domain fragments which have the inhibitory property (187).

Cilostazol inhibits MMP-9 in a dose-dependent manner and on the transcriptional level by

suppressing its promoter and blocking the translocation of NF- κ B (188). Treatment with Cilostazol, reduced MMP-9 activity on and decreased transcript and protein expression (188). The study above presents a mechanism for anti-atherosclerosis by inhibiting monocyte invasion and further differentiation by modulating MMP-9 and TIMP-1 (188).

Anti-hypertensive drug captopril has been shown to inhibit MMP-2 and -9 in a rat model of right ventricular hypertrophy (189), and to decrease plasma MMP-9 in acute myocardial infarction patients (190). Similarly, serum MMP-9 levels were found to decrease in patients with candesartan treatment (191). However, a recent study focusing on the inhibitory action of captopril and lisinopril using purified MMP-2 concluded that these two ACE inhibitors do not act as pharmacological inhibitors of MMP-2 (192).

Hydroxysafflor yellow A, an active ingredients of Chinese herb *Carthamus tinctorius* L, was also shown to inhibit MMP-2 and MMP-9 activity, and also reduces associated apoptosis which helps to mitigate the effects of left ventricular remodeling within the hypertensive heart (193). In addition, kaempferol has shown to act as a pharmacological inhibitor of MMP-2 through the inhibition of the ERK1/2 as well as activator protein-1 pathway making it a good candidate for cardiac disease and cancer (194). Recently, we have shown that hydrogen sulfide treatment confers vascular protection within the kidney and neuronal tissues of hyperhomocysteinemic mice as observed through the decrease of MMP-2 and MMP-9 levels (195-197). Furthermore, phosphinic peptide RXP470.1, is a selective inhibitor of MMP-12 which was shown to mitigate plaque instability in ApoE KO mice (92).

7. SUMMARY AND CONCLUSION

MMPs in general have a fundamental role in matrix homeostasis of vascular health. In disease conditions, MMP activity is altered causing a dysregulation in ECM synthesis and degradation. As a result, vessels become weaker in performing their normal physiological function, such as maintaining blood pressure. In order to keep up with the increased metabolic demand of tumor cells, angiogenesis is facilitated by MMPs in cancer. Similarly, cardiovascular diseases including atherosclerosis, inflammation and ischemia are influenced by MMPs activity. The endogenous inhibitors, TIMPs regulate the expression of MMPs however, they lack specificity. Our current knowledge on interventions to modify MMP activity by pharmacological agents, genetic manipulation and/or by biological agents for prevention or even cure of vascular diseases are limited. Therefore, more research is needed to develop strategies to regulate specific MMPs in a particular disease without affecting other MMPs that are vital for maintaining normal physiological functions.

8. ACKNOWLEDGEMENTS

This work was supported, in part, by National Institutes of Health grants HL-104103 (to Utpal Sen) and HL-108621 (to Suresh C. Tyagi).

9. REFERENCES

1. J. Gross and C. M. Lapiere: Collagenolytic activity in amphibian tissues: a tissue culture assay. *Proc Natl Acad Sci U S A*, 48, 1014-22 (1962)
DOI: 10.1073/pnas.48.6.1014
2. K. Maskos: Crystal structures of MMPs in complex with physiological and pharmacological inhibitors. *Biochimie*, 87(3-4), 249-263 (2005)
DOI: 10.1016/j.biochi.2004.11.019
3. M. S. Razzaque, S. Kumari, C. S. Foster and A. R. Ahmed: Expression profiles of collagens, HSP47, TGF-beta1, MMPs and TIMPs in epidermolysis bullosa acquisita. *Cytokine*, 21(5), 207-13 (2003)
DOI: 10.1016/S1043-4666(03)00034-6
4. I. K. Demedts, A. Morel-Montero, S. Lebecque, Y. Pacheco, D. Cataldo, G. F. Joos, R. A. Pauwels and G. G. Brusselle: Elevated MMP-12 protein levels in induced sputum from patients with COPD. *Thorax*, 61(3), 196-201 (2006)
DOI: 10.1136/thx.2005.042432
5. B. Lovejoy, A. Cleasby, A. M. Hassell, K. Longley, M. A. Luther, D. Weigl, G. McGeehan, A. B. McElroy, D. Drewry, M. H. Lambert and et al.: Structure of the catalytic domain of fibroblast collagenase complexed with an inhibitor. *Science*, 263(5145), 375-7 (1994)
DOI: 10.1126/science.8278810
6. I. Massova, L. P. Kotra, R. Fridman and S. Mobashery: Matrix metalloproteinases: structures, evolution, and diversification. *FASEB J*, 12(12), 1075-95 (1998)
7. C. M. Overall: Molecular determinants of metalloproteinase substrate specificity: matrix metalloproteinase substrate binding domains, modules, and exosites. *Mol Biotechnol*, 22(1), 51-86 (2002)
DOI: 10.1385/MB:22:1:051
8. J. D. Raffetto and R. A. Khalil: Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. *Biochem Pharmacol*, 75(2), 346-59 (2008)
DOI: 10.1016/j.bcp.2007.07.004
9. J. Bujan, F. Jurado, M. J. Gimeno, N. Garcia-Hondurilla, G. Pascual, J. Jimenez and J. M. Bellon: Changes in metalloproteinase (MMP-1, MMP-2) expression in the proximal region of the varicose saphenous vein wall in young subjects. *Phlebology*, 15(2), 64-70 (2000)
DOI: 10.1007/s005230070024
10. A. C. Newby: Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates. *Cardiovasc Res*, 69(3), 614-24 (2006)
DOI: 10.1016/j.cardiores.2005.08.002
11. M. Back, D. F. Ketelhuth and S. Agewall: Matrix metalloproteinases in atherothrombosis. *Prog Cardiovasc Dis*, 52(5), 410-28 (2010)
DOI: 10.1016/j.pcad.2009.12.002
12. T. Alsaigh, E. S. Pocock, J. J. Bergan and G. W. Schmid-Schonbein: Acute venous occlusion enhances matrix metalloprotease activity: Implications on endothelial dysfunction. *Microvasc Res*, 81(1), 108-16 (2011)
DOI: 10.1016/j.mvr.2010.09.010
13. F. A. DeLano and G. W. Schmid-Schonbein: Proteinase activity and receptor cleavage: mechanism for insulin resistance in the spontaneously hypertensive rat. *Hypertension*, 52(2), 415-23 (2008)
DOI: 10.1161/HYPERTENSIONAHA.107.104356
14. P. Clancy, S. W. Seto, S. A. Koblar and J. Gollidge: Role of the angiotensin converting enzyme 1/angiotensin II/angiotensin receptor 1 axis in interstitial collagenase expression in human carotid atheroma. *Atherosclerosis*, 229(2), 331-7 (2013)
DOI: 10.1016/j.atherosclerosis.2013.05.022
15. B. Lavin, M. Gomez, O. M. Pello, B. Castejon, M. J. Piedras, M. Saura and C. Zaragoza: Nitric Oxide Prevents Aortic Neointimal Hyperplasia by Controlling Macrophage Polarization. *Arterioscler Thromb Vasc Biol* (2014)
DOI: 10.1161/ATVBAHA.114.303866
16. K. M. Austin, L. Covic and A. Kuliopulos: Matrix metalloproteases and PAR1 activation. *Blood*, 121(3), 431-9 (2013)
DOI: 10.1182/blood-2012-09-355958

17. A. K. Ahmed, J. L. Haylor, A. M. El Nahas and T. S. Johnson: Localization of matrix metalloproteinases and their inhibitors in experimental progressive kidney scarring. *Kidney Int*, 71(8), 755-763 (2007)
DOI: 10.1038/sj.ki.5002108
18. O. Lenz, S. J. Elliot and W. G. Stetler-Stevenson: Matrix metalloproteinases in renal development and disease. *J Am Soc Nephrol*, 11(3), 574-81 (2000)
19. U. Sen, P. B. Sathnur, S. Kundu, S. Givvimani, D. M. Coley, P. K. Mishra, N. Qipshidze, N. Tyagi, N. Metreveli and S. C. Tyagi: Increased endogenous H₂S generation by CBS, CSE, and 3MST gene therapy improves ex vivo renovascular relaxation in hyperhomocysteinemia. *Am J Physiol Cell Physiol*, 303(1), C41-51 (2012)
DOI: 10.1152/ajpcell.00398.2011
20. T. Quillard, Y. Tesmenitsky, K. Croce, R. Travers, E. Shvartz, K. C. Koskinas, G. K. Sukhova, E. Aikawa, M. Aikawa and P. Libby: Selective inhibition of matrix metalloproteinase-13 increases collagen content of established mouse atherosclerosis. *Arterioscler Thromb Vasc Biol*, 31(11), 2464-72 (2011)
DOI: 10.1161/ATVBAHA.111.231563
21. G. M. Grant, T. A. Giambernardi, A. M. Grant and R. J. Klebe: Overview of expression of matrix metalloproteinases (MMP-17, MMP-18, and MMP-20) in cultured human cells. *Matrix Biol*, 18(2), 145-148 (1999)
DOI: 10.1016/S0945-053X(99)00003-7
22. M. J. Foos, J. R. Hickox, P. G. Mansour, J. R. Slauterbeck and D. M. Hardy: Expression of matrix metalloprotease and tissue inhibitor of metalloprotease genes in human anterior cruciate ligament. *J Ortho Res*, 19(4), 642-649 (2001)
DOI: 10.1016/S0736-0266(00)00071-1
23. S. Kaptoge, S. R. K. Seshasai, P. Gao, D. F. Freitag, A. S. Butterworth, A. Borglykke, E. Di Angelantonio, V. Gudnason, A. Rumley, G. D. O. Lowe, T. Jorgensen and J. Danesh: Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis. *Eur Heart J*, 35(9), 578-U35 (2014)
DOI: 10.1093/eurheartj/eh367
24. S. Lenglet, A. Quercioli, M. Fabre, K. Galan, G. Pelli, A. Nencioni, I. Bauer, A. Pende, M. Python, M. Bertolotto, G. Spinella, B. Pane, D. Palombo, F. Dallegri, F. Mach, N. Vuilleumier and F. Montecucco: Statin Treatment Is Associated with Reduction in Serum Levels of Receptor Activator of NF-kappa B Ligand and Neutrophil Activation in Patients with Severe Carotid Stenosis. *Mediators Inflamm* (2014)
25. E. Scoditti, A. Nestola, M. Massaro, N. Calabriso, C. Storelli, R. De Caterina and M. A. Carluccio: Hydroxytyrosol suppresses MMP-9 and COX-2 activity and expression in activated human monocytes via PKC alpha and PKC beta 1 inhibition. *Atherosclerosis*, 232(1), 17-24 (2014)
DOI: 10.1016/j.atherosclerosis.2013.10.017
26. C. H. Tan, Y. Liu, W. N. Li, F. Deng, X. Liu, X. Wang, Y. J. Gui, L. Qin, C. L. Hu and L. F. Chen: Associations of matrix metalloproteinase-9 and monocyte chemoattractant protein-1 concentrations with carotid atherosclerosis, based on measurements of plaque and intima-media thickness. *Atherosclerosis*, 232(1), 199-203 (2014)
DOI: 10.1016/j.atherosclerosis.2013.11.040
27. D. Palmieri, P. Perego and D. Palombo: Estrogen Receptor Activation Protects Against TNF-alpha-Induced Endothelial Dysfunction. *Angiology*, 65(1), 17-21 (2014)
DOI: 10.1177/0003319713477909
28. L. Sun, S. Chandra and P. Suckosky: Ex vivo evidence for the contribution of hemodynamic shear stress abnormalities to the early pathogenesis of calcific bicuspid aortic valve disease. *PLoS One*, 7(10), e48843 (2012)
DOI: 10.1371/journal.pone.0048843
29. S. T. Gould, S. Srigunapalan, C. A. Simmons and K. S. Anseth: Hemodynamic and cellular response feedback in calcific aortic valve disease. *Circ Res*, 113(2), 186-97 (2013)
DOI: 10.1161/CIRCRESAHA.112.300154
30. L. Sun, N. M. Rajamannan and P. Suckosky: Defining the Role of Fluid Shear Stress in the Expression of Early Signaling Markers for Calcific Aortic Valve Disease. *PLoS One*, 8(12) (2013)
DOI: 10.1371/journal.pone.0084433
31. L. B. Khzam, R. Boulahya, H. Abou-Saleh, A. Hachem, Y. Zaid and Y. Merhi: Soluble CD40 Ligand Stimulates the Pro-Angiogenic Function of Peripheral Blood Angiogenic Outgrowth Cells via Increased Release of

- Matrix Metalloproteinase-9. *PLoS One*, 8(12) (2013)
32. H. Kim, S. Bae, Y. Kim, C. H. Cho, S. J. Kim, Y. J. Kim, S. P. Lee, H. R. Kim, Y. I. Hwang, J. S. Kang and W. J. Lee: Vitamin C prevents stress-induced damage on the heart caused by the death of cardiomyocytes, through down-regulation of the excessive production of catecholamine, TNF-alpha, and ROS production in Gulo (-/-)(Vit C-Insufficient)mice. *Free Radic Biol Med*, 65, 573-583 (2013)
DOI: 10.1016/j.freeradbiomed.2013.07.023
33. P. K. Mishra, S. Givvimani, V. Chavali and S. C. Tyagi: Cardiac matrix: A clue for future therapy. *Biochim Biophys Acta* 1832(12), 2271-2276 (2013)
DOI: 10.1016/j.bbadis.2013.09.004
34. A. L. Jacob-Ferreira and R. Schulz: Activation of intracellular matrix metalloproteinase-2 by reactive oxygen nitrogen species: Consequences and therapeutic strategies in the heart. *Arch Biochem Biophys*, 540(1-2), 82-93 (2013)
DOI: 10.1016/j.abb.2013.09.019
35. J. D. Raffetto, R. L. Ross and R. A. Khalil: Matrix metalloproteinase 2-induced venous dilation via hyperpolarization and activation of K⁺ channels: relevance to varicose vein formation. *J Vasc Surg*, 45(2), 373-80 (2007)
DOI: 10.1016/j.jvs.2006.10.041
36. S. B. Jeon, S. Chun, S. Choi-Kwon, H. S. Chi, H. W. Nah, S. U. Kwon, W. K. Kim and J. S. Kim: Biomarkers and location of atherosclerosis: Matrix metalloproteinase-2 may be related to intracranial atherosclerosis. *Atherosclerosis*, 223(2), 442-447 (2012)
DOI: 10.1016/j.atherosclerosis.2012.04.013
37. K. Shimizu, K. Shimomura, Y. Tokuyama, K. Sakurai, K. Isahaya, S. Takaishi, B. Kato, N. Usuki, T. Shimizu, K. Yamada and Y. Hasegawa: Association between Inflammatory Biomarkers and Progression of Intracranial Large Artery Stenosis after Ischemic Stroke. *J Stroke Cerebrovasc Dis*, 22(3), 211-217 (2013)
DOI: 10.1016/j.jstrokecerebrovasdis.2011.07.019
38. S. H. Heo, C. H. Cho, H. O. Kim, Y. H. Jo, K. S. Yoon, J. H. Lee, J. C. Park, K. C. Park, T. B. Ahn, K. C. Chung, S. S. Yoon and D. I. Chang: Plaque Rupture is a Determinant of Vascular Events in Carotid Artery Atherosclerotic Disease: Involvement of Matrix Metalloproteinases 2 and 9. *J Clin Neurol*, 7(2), 69-76 (2011)
DOI: 10.3988/jcn.2011.7.2.69
39. S. Givvimani, S. Kundu, N. Narayanan, F. Armaghan, N. Qipshidze, S. Pushpakumar, T. P. Vacek and S. C. Tyagi: TIMP-2 mutant decreases MMP-2 activity and augments pressure overload induced LV dysfunction and heart failure. *Arch Physiol Biochem*, 119(2), 65-74 (2013)
DOI: 10.3109/13813455.2012.755548
40. P. Shivshankar, C. Brampton, S. Miyasato, M. Kasper, V. J. Thannickal and C. J. Le Saux: Caveolin-1 Deficiency Protects from Pulmonary Fibrosis by Modulating Epithelial Cell Senescence in Mice. *Am J Respir Cell Mol Biol*, 47(1), 28-36 (2012)
DOI: 10.1165/rcmb.2011-0349OC
41. Y. Gu, G. Q. Zheng, M. J. Xu, Y. Li, X. M. Chen, W. Z. Zhu, Y. Tong, S. K. Chung, K. J. Liu and J. G. Shen: Caveolin-1 regulates nitric oxide-mediated matrix metalloproteinases activity and blood-brain barrier permeability in focal cerebral ischemia and reperfusion injury. *J Neurochem*, 120(1), 147-156 (2012)
DOI: 10.1111/j.1471-4159.2011.07542.x
42. N. Muradashvili, R. Tyagi, N. Metreveli, S. C. Tyagi and D. Lominadze: Ablation of MMP9 gene ameliorates paracellular permeability and fibrinogen-amyloid beta complex formation during hyperhomocysteinemia. *J Cereb Blood Flow Metab*, 34(9), 1472-82 (2014)
DOI: 10.1038/jcbfm.2014.102
43. N. Muradashvili, R. L. Benton, K. E. Saatman, S. C. Tyagi and D. Lominadze: Ablation of matrix metalloproteinase-9 gene decreases cerebrovascular permeability and fibrinogen deposition post traumatic brain injury in mice. *Metab Brain Dis* (2014)
DOI: 10.1007/s11011-014-9550-3
44. P. Giuffrida, P. Biancheri and T. T. MacDonald: Proteases and small intestinal barrier function in health and disease. *Curr Opin Gastroenterol*, 30(2), 147-53 (2014)
DOI: 10.1097/MOG.0000000000000042
45. P. SanSilvestri-Morel, F. Fioretti, A. Rupin, K. Senni, J. N. Fabiani, G. Godeau and T. J. Verbeuren: Comparison of extracellular matrix in skin and saphenous veins from patients with

- varicose veins: does the skin reflect venous matrix changes? *Clinical Science*, 112(3-4), 229-239 (2007)
46. G. Zhang, M. Miyake, A. Lawton, S. Goodison and C. J. Rosser: Matrix metalloproteinase-10 promotes tumor progression through regulation of angiogenic and apoptotic pathways in cervical tumors. *BMC Cancer*, 14(1), 310 (2014)
DOI: 10.1186/1471-2407-14-310
47. B. J. Boucher: Matrix metalloproteinase-10 and microvascular complications of type 1 diabetes: might vitamin D status be relevant? *Diabetologia*, 57(5), 1081-1081 (2014)
DOI: 10.1007/s00125-014-3189-9
48. M. Bobadilla, N. Sainz, J. A. Rodriguez, G. Abizanda, J. Orbe, A. de Martino, J. M. G. Verdugo, J. A. Paramo, F. Prosper and A. Perez-Ruiz: MMP-10 Is Required for Efficient Muscle Regeneration in Mouse Models of Injury and Muscular Dystrophy. *Stem Cells*, 32(2), 447-461 (2014)
DOI: 10.1002/stem.1553
49. J. Tan, E. Buache, F. Alpy, E. Daguene, C. L. Tomasetto, G. S. Ren and M. C. Rio: Stromal matrix metalloproteinase-11 is involved in the mammary gland postnatal development. *Oncogene*, 33(31), 4050-59 (2013)
50. E. R. Motrescu, S. Blaise, N. Etique, N. Messaddeq, M. P. Chenard, I. Stoll, C. Tomasetto and M. C. Rio: Matrix metalloproteinase-11/stromelysin-3 exhibits collagenolytic function against collagen VI under normal and malignant conditions. *Oncogene*, 27(49), 6347-55 (2008)
DOI: 10.1038/ncr.2008.218
51. H. Sato, T. Takino, Y. Okada, J. Cao, A. Shinagawa, E. Yamamoto and M. Seiki: A Matrix Metalloproteinase Expressed on the Surface of Invasive Tumor-Cells. *Nature*, 370(6484), 61-65 (1994)
DOI: 10.1038/370061a0
52. I. Anik, S. Kokturk, H. Genc, B. Cabuk, K. Koc, S. Yavuz, S. Ceylan, S. Ceylan, L. Kamaci and Y. Anik: Immunohistochemical analysis of TIMP-2 and collagen types I and IV in experimental spinal cord ischemia-reperfusion injury in rats. *J Spin Cord Med*, 34(3), 257-264 (2011)
DOI: 10.1179/107902611X12972448729648
53. E. Candelario-Jalil, Y. Yang and G. A. Rosenberg: Diverse Roles of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Neuroinflammation and Cerebral Ischemia. *Neuroscience*, 158(3), 983-994 (2009)
DOI: 10.1016/j.neuroscience.2008.06.025
54. J. A. Thompson, B. S. Richardson, R. Gagnon and T. R. H. Regnault: Chronic intrauterine hypoxia interferes with aortic development in the late gestation ovine fetus. *J Physiol-London*, 589(13), 3319-3332 (2011)
DOI: 10.1113/jphysiol.2011.210625
55. R. Yang, H. Liu, I. Williams and B. Chaqour: Matrix metalloproteinase-2 expression and apoptogenic activity in retinal pericytes: implications in diabetic retinopathy. *Ann N Y Acad Sci*, 1103, 196-201 (2007)
DOI: 10.1196/annals.1394.000
56. J. H. Park, S. M. Park, S. H. Park, K. H. Cho and S. T. Lee: Cleavage and functional loss of human apolipoprotein E by digestion of matrix metalloproteinase-14. *Proteomics*, 8(14), 2926-2935 (2008)
DOI: 10.1002/pmic.200700487
57. J. H. Park, S. M. Park, K. H. Park, K. H. Cho and S. T. Lee: Analysis of apolipoprotein A-I as a substrate for matrix metalloproteinase-14. *Biochem Biophys Res Comm*, 409(1), 58-63 (2011)
DOI: 10.1016/j.bbrc.2011.04.105
58. T. Waldow, W. Witt, A. Buzin, A. Ulmer and K. Matschke: Prevention of ischemia/reperfusion-induced accumulation of matrix metalloproteinases in rat lung by preconditioning with nitric oxide. *J Surg Res*, 152(2), 198-208 (2009)
DOI: 10.1016/j.jss.2008.03.014
59. J. Lin, H. B. Davis, Q. X. Dai, Y. M. Chou, T. Craig, C. Hinojosa-Laborde and M. L. Lindsey: Effects of early and late chronic pressure overload on extracellular matrix remodeling. *Hypertens Res*, 31(6), 1225-1231 (2008)
DOI: 10.1291/hypres.31.1225
60. K. Straat, R. de Klark, S. Gredmark-Russ, P. Eriksson and C. Soderberg-Naucler: Infection with Human Cytomegalovirus Alters the MMP-9/TIMP-1 Balance in Human Macrophages. *J Virol*, 83(2), 830-835 (2009)
DOI: 10.1128/JVI.01363-08

61. M. Feng, X. J. Cai, W. Zhang, X. L. Liu, L. Chen, Y. Zhang, M. X. Zhang and M. Zhang: Interleukin-6 enhances matrix metalloproteinase-14 expression via the RAF-mitogen-activated protein kinase kinase-extracellular signal-regulated kinase 1/2-activator protein-1 pathway. *Clin Exp Pharmacol Physiol*, 37(2), 162-166 (2010)
DOI: 10.1111/j.1440-1681.2009.05246.x
62. M. Zack, B. B. Boyanovsky, P. Shridas, W. Bailey, K. Forrest, D. A. Howatt, M. H. Gelb, F. C. de Beer, A. Daugherty and N. R. Webb: Group X secretory phospholipase A(2) augments angiotensin II-induced inflammatory responses and abdominal aortic aneurysm formation in apoE-deficient mice. *Atherosclerosis*, 214(1), 58-64 (2011)
DOI: 10.1016/j.atherosclerosis.2010.08.054
63. V. Sood, C. E. Luke, K. B. Deatrick, J. Baldwin, E. M. Miller, M. Elflin, G. R. Upchurch, T. W. Wakefield and P. K. Henke: Urokinase plasminogen activator independent early experimental thrombus resolution: MMP2 as an alternative mechanism. *Thromb Haemost*, 104(6), 1174-1183 (2010)
DOI: 10.1160/TH10-03-0184
64. M. Pons, S. W. Cousins, O. Alcazar, G. E. Striker and M. E. Marin-Castano: Angiotensin II-induced MMP-2 activity and MMP-14 and basigin protein expression are mediated via the angiotensin II receptor type 1-mitogen-activated protein kinase 1 pathway in retinal pigment epithelium: implications for age-related macular degeneration. *Am J Pathol*, 178(6), 2665-81 (2011)
DOI: 10.1016/j.ajpath.2011.02.006
65. S. M. Cork, B. Kaur, N. S. Devi, L. Cooper, J. H. Saltz, E. M. Sandberg, S. Kaluz and E. G. Van Meir: A proprotein convertase/MMP-14 proteolytic cascade releases a novel 40 kDa vasculostatin from tumor suppressor BAI1. *Oncogene*, 31(50), 5144-52 (2012)
DOI: 10.1038/onc.2012.1
66. C. S. Ceron, E. Rizzi, D. A. Guimaraes, A. Martins-Oliveira, S. B. Cau, J. Ramos, R. F. Gerlach and J. E. Tanus-Santos: Time course involvement of matrix metalloproteinases in the vascular alterations of renovascular hypertension. *Matrix Biol*, 31(4), 261-70 (2012)
DOI: 10.1016/j.matbio.2012.01.009
67. S. Duarte, X. D. Shen, C. Fondevila, R. W. Busuttil and A. J. Coito: Fibronectin-alpha4beta1 interactions in hepatic cold ischemia and reperfusion injury: regulation of MMP-9 and MT1-MMP via the p38 MAPK pathway. *Am J Transplant*, 12(10), 2689-99 (2012)
DOI: 10.1111/j.1600-6143.2012.04161.x
68. A. Radziwon-Balicka, C. Ramer, C. Moncada de la Rosa, B. Zielnik-Drabik and P. Jurasz: Angiostatin inhibits endothelial MMP-2 and MMP-14 expression: a hypoxia specific mechanism of action. *Vascul Pharmacol*, 58(4), 280-91 (2013)
DOI: 10.1016/j.vph.2012.11.003
69. J. Xu, Y. Sun, T. Wang and G. Liu: Prevention of neointimal hyperplasia in balloon-injured rat carotid artery via small interference RNA mediated downregulation of osteopontin gene. *Mol Cell Biochem*, 377(1-2), 1-10 (2013)
DOI: 10.1007/s11010-012-1554-x
70. X. S. Vasko R, Chen J, Lin CH, Ratliff B, Rabadi M, Maizel J, Tanokuchi R, Zhang F, Cao J, Goligorsky MS.: Endothelial sirtuin 1 deficiency perpetrates nephrosclerosis through downregulation of matrix metalloproteinase-14: relevance to fibrosis of vascular senescence. *J Am Soc Nephrol*, 25(2), 276-91 (2014)
DOI: 10.1681/ASN.2013010069
71. Y. N. Fu, J. A. Nagy, L. F. Brown, S. C. Shih, P. Y. Johnson, C. K. Chan, H. F. Dvorak and T. N. Wight: Proteolytic Cleavage of Versican and Involvement of ADAMTS-1 in VEGF-A/VPF-Induced Pathological Angiogenesis. *J Histochem Cytochem*, 59(5), 463-473 (2011)
DOI: 10.1369/0022155411401748
72. S. K. Shin JI, Kim H, Cho NH, Kim J, Kim HS, Lee JS: The gene expression profile of matrix metalloproteinases and their inhibitors in children with Henoch-Schönlein purpura. *Br J Dermatol*, 164(2), 1348-55 (2011)
DOI: 10.1111/j.1365-2133.2011.10295.x
73. Y. B. Zhang, W. Li, L. Q. Yao, X. L. Zhao, B. Wang, H. K. Li, Y. Ning, E. Song and X. X. Zhang: Expression changes and roles of matrix metalloproteinases in a rat model of traumatic deep vein thrombosis. *Chin J Traumatol*, 13(3), 188-92 (2010)
74. L. Host, A. Paye, B. Detry, S. Blacher, C. Munaut, J. M. Foidart, M. Seiki, N. E. Sounni and A. Noel: The proteolytic activity of

- MT4-MMP is required for its pro-angiogenic and pro-metastatic promoting effects. *Int J Canc*, 131(7), 1537-1548 (2012)
DOI: 10.1002/ijc.27436
75. H. Abdul-Hussien, R. Hanemaaijer, J. H. Verheijen, J. H. van Bockel, R. H. Geelkerken and J. H. N. Lindeman: Doxycycline therapy for abdominal aneurysm: Improved proteolytic balance through reduced neutrophil content. *J Vasc Surg*, 49(3), 741-749 (2009)
DOI: 10.1016/j.jvs.2008.09.055
76. S.-N. G. Huang WC, Susana A, Johnson JL, Newby AC.: Classical macrophage activation up-regulates several matrix metalloproteinases through mitogen activated protein kinases and nuclear factor- κ B. *PLoS One*, 7(8)(2012)
77. Y. A. Chiao, R. Zamilpa, E. F. Lopez, Q. X. Dai, G. P. Escobar, K. Hakala, S. T. Weintraub and M. L. Lindsey: In vivo Matrix Metalloproteinase-7 Substrates Identified in the Left Ventricle Post-Myocardial Infarction Using Proteomics. *J Proteome Res*, 9(5), 2649-2657 (2010)
DOI: 10.1021/pr100147r
78. A. Yabluchanskiy, Y. Li, L. E. de Castro Bras, K. Hakala, S. T. Weintraub and M. L. Lindsey: Proteomic analysis of the left ventricle post-myocardial infarction to identify in vivo candidate matrix metalloproteinase substrates. *Methods Mol Biol*, 1066, 185-99 (2013)
DOI: 10.1007/978-1-62703-604-7_16
79. H. L. Su K, Li W, Yan X, Li X, Zhang Z, Jin F, Lei J, Ba G, Liu B, Wang X, Wang Y.: TC-1 (c8orf4) enhances aggressive biologic behavior in lung cancer through the Wnt/ β -catenin pathway. *J Surg Res*, 185(1), 255-63 (2012)
DOI: 10.1016/j.jss.2013.05.075
80. R. Reindel, S. C. Baker, K. Y. Kim, C. A. Rowley, S. T. Shulman, J. M. Orenstein, E. J. Perlman, M. W. Lingen and A. H. Rowley: Integrins α 4 and α 5, collagen1A1, and matrix metalloproteinase 7 are upregulated in acute Kawasaki disease vasculopathy. *Pediatr Res*, 73(3), 332-6 (2013)
DOI: 10.1038/pr.2012.185
81. W. A. LaFramboise, R. Dhir, L. A. Kelly, P. Petrosko, J. M. Krill-Burger, C. M. Sciulli, M. A. Lyons-Weiler, U. R. Chandran, A. Lomakin, R. V. Masterson, O. C. Marroquin, S. R. Mulukutla and D. M. McNamara: Serum protein profiles predict coronary artery disease in symptomatic patients referred for coronary angiography. *BMC Med*, 10, 157 (2012)
DOI: 10.1186/1741-7015-10-157
82. A. Razuvaev, J. Ekstrand, L. Folkersen, H. Agardh, D. Markus, J. Swedenborg, G. K. Hansson, A. Gabrielsen, G. Paulsson-Berne, J. Roy and U. Hedin: Correlations Between Clinical Variables and Gene-expression Profiles in Carotid Plaque Instability. *Eur J Vasc Endovasc Surg*, 42(6), 722-730 (2011)
DOI: 10.1016/j.ejvs.2011.05.023
83. S. Tong, H. J. Neboori, E. D. Tran and G. W. Schmid-Schonbein: Constitutive Expression and Enzymatic Cleavage of ICAM-1 in the Spontaneously Hypertensive Rat. *J Vasc Res*, 48(5), 386-396 (2011)
DOI: 10.1159/000323474
84. P. Chieng-Yane, A. Bocquet, R. Letienne, T. Bourbon, S. Sablayrolles, M. Perez, S. N. Hatem, A. M. Lompre, B. Le Grand and M. David-Dufilho: Protease-activated receptor-1 antagonist F 16618 reduces arterial restenosis by down-regulation of tumor necrosis factor α and matrix metalloproteinase 7 expression, migration, and proliferation of vascular smooth muscle cells. *J Pharmacol Exp Ther*, 336(3), 643-51 (2011)
DOI: 10.1124/jpet.110.175182
85. J. Odenbach, X. Wang, S. Cooper, F. L. Chow, T. Oka, G. Lopaschuk, Z. Kassiri and C. Fernandez-Patron: MMP-2 mediates angiotensin II-induced hypertension under the transcriptional control of MMP-7 and TACE. *Hypertension*, 57(1), 123-30 (2011)
DOI: 10.1161/HYPERTENSIONAHA.110.159525
86. P. M. Vanhoutte: Regeneration of the endothelium in vascular injury. *Cardiovasc Drugs Ther*, 24(4), 299-303 (2010)
DOI: 10.1007/s10557-010-6257-5
87. S. F. Rodrigues, E. D. Tran, Z. B. Fortes and G. W. Schmid-Schonbein: Matrix metalloproteinases cleave the β 2-adrenergic receptor in spontaneously hypertensive rats. *Am J Physiol Heart Circ Physiol*, 299(1), H25-35 (2010)
DOI: 10.1152/ajpheart.00620.2009
88. E. Pirila, J. T. Korpi, T. Korkiamaki, T. Jahkola, A. Gutierrez-Fernandez, C. Lopez-Otin,

- U. Saarialho-Kere, T. Salo and T. Sorsa: Collagenase-2 (MMP-8) and matrilysin-2 (MMP-26) expression in human wounds of different etiologies. *Wound Repair Regen*, 15(1), 47-57 (2007)
DOI: 10.1111/j.1524-475X.2006.00184.x
89. A. S. Krishnatry, D. A. Brazeau and H. L. Fung: Broad regulation of matrix and adhesion molecules in THP-1 human macrophages by nitroglycerin. *Nitric Oxide*, 22(1), 11-7 (2010)
DOI: 10.1016/j.niox.2009.10.004
90. M. Tanskanen, L. Myllykangas, U. Saarialho-Kere and A. Paetau: Matrix metalloproteinase-beta19 expressed in cerebral amyloid angiopathy. *Amyloid*, 18(1), 3-9 (2011)
DOI: 10.3109/13506129.2010.541960
91. S. D. Shapiro, D. K. Kobayashi and T. J. Ley: Cloning and characterization of a unique elastolytic metalloproteinase produced by human alveolar macrophages. *J Biol Chem*, 268(32), 23824-9 (1993)
92. J. L. Johnson, L. Devel, B. Czarny, S. J. George, C. L. Jackson, V. Rogakos, F. Beau, A. Yiotakis, A. C. Newby and V. Dive: A selective matrix metalloproteinase-12 inhibitor retards atherosclerotic plaque development in apolipoprotein E-knockout mice. *Arterioscler Thromb Vasc Biol*, 31(3), 528-35 (2011)
DOI: 10.1161/ATVBAHA.110.219147
93. W. Jithpratuck, Y. Elshenawy, H. Saleh, G. Youngberg, D. S. Chi and G. Krishnaswamy: The clinical implications of adult-onset henoch-schonelin purpura. *Clin Mol Allergy*, 9(1), 9 (2011)
DOI: 10.1186/1476-7961-9-9
94. M. Proietta, L. Tritapepe, N. Cifani, L. Ferri, M. Taurino and F. Del Porto: MMP-12 as a new marker of Stanford-A acute aortic dissection. *Ann Med*, 46(1), 44-48 (2014)
DOI: 10.3109/07853890.2013.876728
95. K. T. Ji, Y. Zhang, F. C. Jiang, L. Qian, H. H. Guo, J. J. Hu, L. M. Liao and J. F. Tang: Exploration of the mechanisms by which 3,4-benzopyrene promotes angiotensin II-induced abdominal aortic aneurysm formation in mice. *J Vasc Surg*, 59(2), 492-499 (2014)
DOI: 10.1016/j.jvs.2013.03.022
96. Y. Song, Y. H. Xie, F. Liu, C. Zhao, R. Yu, S. Ban, Q. F. Ye, J. X. Wen, H. B. Wan, X. Li, R. W. Ma and Z. H. Meng: Expression of matrix metalloproteinase-12 in aortic dissection. *BMC Cardiovasc Disord*, 13 (2013)
97. M. Tao, P. Yu, B. T. Nguyen, B. Mizrahi, N. Savion, F. D. Kolodgie, R. Virmani, S. Hao, C. K. Ozaki and J. Schneiderman: Locally Applied Leptin Induces Regional Aortic Wall Degeneration Preceding Aneurysm Formation in Apolipoprotein E-Deficient Mice. *Arterioscler Thromb Vasc Biol*, 33(2), 311(2013)
98. T. Wolak, N. Sion-Vardi, V. Novack, G. Greenberg, G. Szendro, T. Tarnovskii, O. Nov, I. Shelef, E. Paran and A. Rudich: N-Terminal Rather Than Full-Length Osteopontin or Its C-Terminal Fragment Is Associated With Carotid-Plaque Inflammation in Hypertensive Patients. *Am J Hypertens*, 26(3), 326-333 (2013)
DOI: 10.1093/ajh/hps043
99. V. P. W. Scholtes, J. L. Johnson, N. Jenkins, G. B. Sala-Newby, J. P. P. M. de Vries, G. J. de Borst, D. P. V. de Kleijn, F. L. Moll, G. Pasterkamp and A. C. Newby: Carotid Atherosclerotic Plaque Matrix Metalloproteinase-12-Positive Macrophage Subpopulation Predicts Adverse Outcome After Endarterectomy. *J Am Heart Assoc*, 1(6) (2012)
DOI: 10.1161/JAHA.112.001040
100. R. M. Korol, P. B. Canham, L. Liu, K. Viswanathan, G. G. Ferguson, R. R. Hammond, H. M. Finlay, H. V. Baker, C. Lopez and A. R. Lucas: Detection of Altered Extracellular Matrix in Surface Layers of Unstable Carotid Plaque: An Optical Spectroscopy, Birefringence and Microarray Genetic Analysis. *Photochem Photobiol*, 87(5), 1164-1172 (2011)
DOI: 10.1111/j.1751-1097.2011.00960.x
101. J. M. Li, J. J. Wang, Q. S. Peng, C. Chen, M. B. Humphrey, J. Heinecke and S. X. Zhang: Macrophage Metalloelastase (MMP-12) Deficiency Mitigates Retinal Inflammation and Pathological Angiogenesis in Ischemic Retinopathy. *PLoS One*, 7(12) (2012)
102. J. W. Shin, H. C. Kang, J. Shim and N. W. Sohn: *Scutellaria baicalensis* Attenuates Blood-Brain Barrier Disruption after Intracerebral Hemorrhage in Rats. *Am J Chin Med*, 40(1), 85-96 (2012)
DOI: 10.1142/S0192415X12500073
103. P. Svedin, H. Hagberg and C. Mallard:

- Expression of MMP-12 after Neonatal Hypoxic-Ischemic Brain Injury in Mice. *Dev Neurosci*, 31(5), 427-436 (2009)
DOI: 10.1159/000232561
104. M. Manetti, S. Guiducci, E. Romano, S. Bellando-Randone, M. L. Conforti, L. Ibba-Manneschi and M. Matucci-Cerinic: Increased serum levels and tissue expression of matrix metalloproteinase-12 in patients with systemic sclerosis: correlation with severity of skin and pulmonary fibrosis and vascular damage. *Ann Rheum Dis*, 71(6), 1064-1072 (2012)
DOI: 10.1136/annrheumdis-2011-200837
105. J. S. Ikonomidis, J. M. Ruddy, S. M. Benton, J. Arroyo, T. A. Brinsa, R. E. Stroud, A. Zeeshan, J. E. Bavaria, J. H. Gorman, R. C. Gorman, F. G. Spinale and J. A. Jones: Aortic Dilatation With Bicuspid Aortic Valves: Cusp Fusion Correlates to Matrix Metalloproteinases and Inhibitors INVITED COMMENTARY. *Ann Thorac Surg*, 93(2), 457-464 (2012)
DOI: 10.1016/j.athoracsur.2011.09.057
106. J. Ryan, F. Y. Ma, J. Kanellis, M. Delgado, K. Blease and D. J. Nikolic-Paterson: Spleen tyrosine kinase promotes acute neutrophil-mediated glomerular injury via activation of JNK and p38 MAPK in rat nephrotoxic serum nephritis. *Lab Invest*, 91(12), 1727-1738 (2011)
DOI: 10.1038/labinvest.2011.137
107. C. Shimizu, T. Matsubara, Y. Onouchi, S. Jain, S. Sun, C. M. Nievergelt, H. Shike, V. H. Brophy, T. Takegawa, S. Furukawa, T. Akagi, J. W. Newburger, A. L. Baker, D. Burgner, M. L. Hibberd, S. Davila, M. Levin, M. Mamtani, W. J. He, S. K. Ahuja and J. C. Burns: Matrix metalloproteinase haplotypes associated with coronary artery aneurysm formation in patients with Kawasaki disease. *J Hum Genet*, 55(12), 779-784 (2010)
DOI: 10.1038/jhg.2010.109
108. G. Arunachalam, I. K. Sundar, J. W. Hwang, H. W. Yao and I. Rahman: Emphysema is associated with increased inflammation in lungs of atherosclerosis-prone mice by cigarette smoke: implications in comorbidities of COPD. *J Inflamm-London*, 7 (2010)
109. N. S. Pauwels, K. R. Bracke, T. Maes, G. R. Van Pottelberge, C. Garlanda, A. Mantovani, G. F. Joos and G. G. Brusselle: Cigarette smoke induces PTX3 expression in pulmonary veins of mice in an IL-1 dependent manner. *Respir Res*, 11 (2010)
110. V. Jackson, T. Olsson, S. Kurtovic, L. Folkersen, V. Paloschi, D. Wagsater, A. Franco-Cereceda and P. Eriksson: Matrix metalloproteinase 14 and 19 expression is associated with thoracic aortic aneurysms. *J Thorac Cardiovasc Surg*, 144(2), 459-466 (2012)
DOI: 10.1016/j.jtcvs.2011.08.043
111. W. A. Roscoe, M. E. Welsh, D. E. Carter and S. J. Karlik: VEGF and angiogenesis in acute and chronic MOG((35-55))peptide induced EAE. *J Neuroimmunol*, 209(1-2), 6-15 (2009)
DOI: 10.1016/j.jneuroim.2009.01.009
112. M. S. Kolb C, Krawinkel U, Sedlacek R.: Matrix metalloproteinase-19 in capillary endothelial cells: expression in acutely, but not in chronically, inflamed synovium. *Exp Cell Res*, 250(1), 122-30 (1999)
DOI: 10.1006/excr.1999.4493
113. L. Hegedus, H. Cho, X. Xie and G. L. Eliceiri: Additional MDA-MB-231 breast cancer cell matrix metalloproteinases promote invasiveness. *J Cell Physiol*, 216(2), 480-5 (2008)
DOI: 10.1002/jcp.21417
114. K. Ahokas, J. Lohi, H. Lohi, O. Elomaa, M. L. Karjalainen-Lindsberg, J. Kere and U. Saarialho-Kere: Matrix metalloproteinase-21, the human orthologue for XMMP, is expressed during fetal development and in cancer. *Gene*, 301(1-2), 31-41 (2002)
DOI: 10.1016/S0378-1119(02)01088-0
115. T. Kuivanen, K. Ahokas, S. Virolainen, T. Jahkola, E. Holttä, O. Saksela and U. Saarialho-Kere: MMP-21 is upregulated at early stages of melanoma progression but disappears with more aggressive phenotype. *Virchows Archiv*, 447(6), 954-960 (2005)
DOI: 10.1007/s00428-005-0046-8
116. T. Skoog, O. Elomaa, S. M. Pasonen-Seppanen, S. Forsberg, K. Ahokas, L. Jeskanen, J. Parssinen, I. Tiala, O. Rollman, J. Lohi and U. Saarialho-Kere: Matrix Metalloproteinase-21 Expression Is Associated with Keratinocyte Differentiation and Upregulated by Retinoic Acid in HaCaT Cells. *J Invest Dermatol*, 129(1), 119-130 (2009)
DOI: 10.1038/jid.2008.206
117. G. N. Marchenko, N. D. Marchenko

- and A. Y. Strongin: The structure and regulation of the human and mouse matrix metalloproteinase-21 gene and protein. *Biochem J*, 372(Pt 2), 503-15 (2003)
DOI: 10.1042/BJ20030174
118. Y. Huang, W. H. Li, D. K. Chu, J. Y. Zheng, G. Ji, M. B. Li, H. W. Zhang, W. Z. Wang, J. J. Du and J. P. Li: Overexpression of Matrix Metalloproteinase-21 is Associated with Poor Overall Survival of Patients with Colorectal Cancer. *J Gastrointest Surg*, 15(7), 1188-1194 (2011)
DOI: 10.1007/s11605-011-1519-5
119. T. Wu, Y. Li, J. G. Lu, Q. Qiao, G. Q. Bao, N. Wang, X. L. He and X. L. Du: Increased MMP-21 expression is associated with poor overall survival of patients with gastric cancer. *Med Oncol*, 30(1) (2013)
DOI: 10.1007/s12032-012-0323-8
120. R. Gururajan, J. Grenet, J. M. Lahti and V. J. Kidd: Isolation and characterization of two novel metalloproteinase genes linked to the Cdc2L locus on human chromosome 1p36.3. *Genomics*, 52(1), 101-6 (1998)
DOI: 10.1006/geno.1998.5401
121. M. Gajecka, W. Yu, B. C. Ballif, C. D. Glotzbach, K. A. Bailey, C. A. Shaw, C. D. Kashork, H. A. Heilstedt, D. A. Ansel, A. Theisen, R. Rice, D. P. Rice and L. G. Shaffer: Delineation of mechanisms and regions of dosage imbalance in complex rearrangements of 1p36 leads to a putative gene for regulation of cranial suture closure. *Eur J Hum Genet*, 13(2), 139-49 (2005)
DOI: 10.1038/sj.ejhg.5201302
122. J. Lohi, C. L. Wilson, J. D. Roby and W. C. Parks: Epilysin, a novel human matrix metalloproteinase (MMP-28) expressed in testis and keratinocytes and in response to injury. *J Biol Chem*, 276(13), 10134-10144 (2001)
DOI: 10.1074/jbc.M001599200
123. F. Bernal, H. P. Hartung and B. C. Kieseier: Tissue mRNA expression in rat of newly described matrix metalloproteinases. *Biol Res*, 38(2-3), 267-271 (2005)
DOI: 10.4067/S0716-97602005000200016
124. A. K. Murugan, C. F. Yang and M. Z. Xing: Mutational analysis of the GNA11, MMP27, FGD1, TRRAP and GRM3 genes in thyroid cancer. *Oncol Lett*, 6(2), 437-441 (2013)
125. Y. G. Ma, G. V. Halade, J. H. Zhang, T. A. Ramirez, D. Levin, A. Voorhees, Y. F. Jin, H. C. Han, A. M. Manicone and M. L. Lindsey: Matrix Metalloproteinase-28 Deletion Exacerbates Cardiac Dysfunction and Rupture After Myocardial Infarction in Mice by Inhibiting M2 Macrophage Activation. *Circ Res*, 112(4), 675 (2013)
126. G. Poli, F. Biasi and G. Leonarduzzi: Oxysterols in the pathogenesis of major chronic diseases. *Redox Biol*, 1(1), 125-130 (2013)
DOI: 10.1016/j.redox.2012.12.001
127. Z. Li, Y. Guo, H. Jiang, T. Zhang, C. Jin, C. Y. Young and H. Yuan: Differential regulation of MMPs by E2F1, Sp1 and NF-kappa B controls the small cell lung cancer invasive phenotype. *BMC Cancer*, 14, 276 (2014)
DOI: 10.1186/1471-2407-14-276
128. R. A. Williamson, G. Martorell, M. D. Carr, G. Murphy, A. J. Docherty, R. B. Freedman and J. Feeney: Solution structure of the active domain of tissue inhibitor of metalloproteinases-2. A new member of the OB fold protein family. *Biochemistry*, 33(39), 11745-59 (1994)
DOI: 10.1021/bi00205a010
129. K. Brew, D. Dinakarandian and H. Nagase: Tissue inhibitors of metalloproteinases: evolution, structure and function. *Biochim Biophys Acta*, 1477(1-2), 267-83 (2000)
DOI: 10.1016/S0167-4838(99)00279-4
130. R. Visse and H. Nagase: Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. *Circ Res*, 92(8), 827-39 (2003)
DOI: 10.1161/01.RES.0000070112.80711.3D
131. H. Nagase, R. Visse and G. Murphy: Structure and function of matrix metalloproteinases and TIMPs. *Cardiovasc Res*, 69(3), 562-73 (2006)
DOI: 10.1016/j.cardiores.2005.12.002
132. M. A. Lafleur, M. D. Hollenberg, S. J. Atkinson, K. V. G. Murphy and D. R. Edwards: Activation of pro-(matrix metalloproteinase-2) (pro-MMP-2) by thrombin is membrane-type-MMP-dependent in human umbilical vein endothelial cells and generates a distinct 63 kDa active species. *Biochem J*, 357, 107-115 (2001)
DOI: 10.1042/0264-6021:3570107
133. D. D. Li, J. N. Song, H. Huang, X. Y. Guo, J.

- Y. An, M. Zhang, Y. Li, P. Sun, H. G. Pang, Y. L. Zhao and J. F. Wang: The roles of MMP-9/TIMP-1 in cerebral edema following experimental acute cerebral infarction in rats. *Neurosci Lett*, 550, 168-72 (2013)
DOI: 10.1016/j.neulet.2013.06.034
134. H. M. Xu, Y. Zhao, X. M. Zhang, T. Zhu and W. G. Fu: Polymorphisms in MMP-9 and TIMP-2 in Chinese patients with varicose veins. *J Surg Res*, 168(1), e143-8 (2011)
DOI: 10.1016/j.jss.2010.11.002
135. V. L. Andrade, E. Petruceli, V. A. Belo, C. M. Andrade-Fernandes, C. V. Caetano Russi, A. A. Bosco, J. E. Tanus-Santos and V. C. Sandrim: Evaluation of plasmatic MMP-8, MMP-9, TIMP-1 and MPO levels in obese and lean women. *Clin Biochem*, 45(6), 412-5 (2012)
DOI: 10.1016/j.clinbiochem.2012.01.008
136. Z. Li, S. Guo, F. Yao, Y. Zhang and T. Li: Increased ratio of serum matrix metalloproteinase-9 against TIMP-1 predicts poor wound healing in diabetic foot ulcers. *J Diabetes Complications*, 27(4), 380-2 (2013)
DOI: 10.1016/j.jdiacomp.2012.12.007
137. M. L. Lamfers, J. M. Grimbergen, M. C. Aalders, M. J. Havenga, M. R. de Vries, L. G. Huisman, V. W. van Hinsbergh and P. H. Quax: Gene transfer of the urokinase-type plasminogen activator receptor-targeted matrix metalloproteinase inhibitor TIMP-1. ATF suppresses neointima formation more efficiently than tissue inhibitor of metalloproteinase-1. *Circ Res*, 91(10), 945-52 (2002)
DOI: 10.1161/01.RES.0000041418.51906.57
138. D. Eefting, M. R. de Vries, J. M. Grimbergen, J. C. Karper, J. H. van Bockel and P. H. Quax: In vivo suppression of vein graft disease by nonviral, electroporation-mediated, gene transfer of tissue inhibitor of metalloproteinase-1 linked to the amino terminal fragment of urokinase (TIMP-1. ATF), a cell-surface directed matrix metalloproteinase inhibitor. *J Vasc Surg*, 51(2), 429-37 (2010)
DOI: 10.1016/j.jvs.2009.09.026
139. V. J. J. Cadete, S. A. Arcand, B. M. Chaharyn, A. Doroszko, J. Sawicka, D. D. Mousseau and G. Sawicki: Matrix Metalloproteinase-2 Is Activated During Ischemia/Reperfusion in a Model of Myocardial Infarction. *Can J Cardiol*, 29(11), 1495-1503 (2013)
DOI: 10.1016/j.cjca.2013.03.014
140. C. K. Samadzadeh KM, Nguyen AT, Baker PM, Bains S, Lee ES.: Monocyte activity is linked with abdominal aortic aneurysm diameter. *J Surg Res* (2014)
141. C. L. Gao L, Lu ZZ, Gao H, Wu L, Chen YX, Zhang CM, Jiang YK, Jing Q, Zhang Y, Yang HT.: Activation of α 1B-adrenoceptors contributes to intermittent hypobaric hypoxia-improved post-ischemic myocardial performance via inhibiting MMP-2 activation. *Am J Physiol Heart Circ Physiol* (2014)
142. C. R. Foster, L. L. Daniel, C. R. Daniels, S. Dalal, M. Singh and K. Singh: Deficiency of Ataxia Telangiectasia Mutated Kinase Modulates Cardiac Remodeling Following Myocardial Infarction: Involvement in Fibrosis and Apoptosis. *PLoS One*, 8(12) (2013)
DOI: 10.1371/journal.pone.0083513
143. N. Muradashvili, R. L. Benton, R. Tyagi, S. C. Tyagi and D. Lominadze: Elevated level of fibrinogen increases caveolae formation; role of matrix metalloproteinase-9. *Cell Biochem Biophys*, 69(2), 283-94 (2014)
DOI: 10.1007/s12013-013-9797-z
144. H. Yao, J. W. Hwang, I. K. Sundar, A. E. Friedman, M. W. McBurney, L. Guarente, W. Gu, V. L. Kinnula and I. Rahman: SIRT1 redresses the imbalance of tissue inhibitor of matrix metalloproteinase-1 and matrix metalloproteinase-9 in the development of mouse emphysema and human COPD. *Am J Physiol Lung Cell Mol Physiol*, 305(9), L615-24 (2013)
DOI: 10.1152/ajplung.00249.2012
145. E. C. El Hajj, M. C. El Hajj, T. G. Voloshenyuk, A. J. Mouton, E. Khoutorova, P. E. Molina, N. W. Gilpin and J. D. Gardner: Alcohol modulation of cardiac matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs favors collagen accumulation. *Alcohol Clin Exp Res*, 38(2), 448-56 (2014)
DOI: 10.1111/acer.12239
146. S. Udali, P. Guarini, S. Moruzzi, S. W. Choi and S. Friso: Cardiovascular epigenetics: from DNA methylation to microRNAs. *Mol Aspects Med*, 34(4), 883-901 (2013)
DOI: 10.1016/j.mam.2012.08.001

147. L. W. T.V. Shiva Shankar: Epigenetic modulators mitigate angiogenesis through a complex transcriptomic network. *Vasc Pharmacol*, 60, 57-66 (2014)
DOI: 10.1016/j.vph.2014.01.003
148. D. M. Hellebrekers, K. W. Jair, E. Vire, S. Eguchi, N. T. Hoebers, M. F. Fraga, M. Esteller, F. Fuks, S. B. Baylin, M. van Engeland and A. W. Griffioen: Angiostatic activity of DNA methyltransferase inhibitors. *Mol Cancer Ther*, 5(2), 467-75 (2006)
DOI: 10.1158/1535-7163.MCT-05-0417
149. L. Ivanciu, R. D. Gerard, H. Tang, F. Lupu and C. Lupu: Adenovirus-mediated expression of tissue factor pathway inhibitor-2 inhibits endothelial cell migration and angiogenesis. *Arterioscler Thromb Vasc Biol*, 27(2), 310-6 (2007)
DOI: 10.1161/01.ATV.0000254147.89321.cf
150. D. Miyazaki, A. Nakamura, K. Fukushima, K. Yoshida, S. Takeda and S. Ikeda: Matrix metalloproteinase-2 ablation in dystrophin-deficient mdx muscles reduces angiogenesis resulting in impaired growth of regenerated muscle fibers. *Hum Mol Genet*, 20(9), 1787-99 (2011)
DOI: 10.1093/hmg/ddr062
151. C. Gupta, J. Kaur and K. Tikoo: Regulation of MDA-MB-231 cell proliferation by GSK-3 β involves epigenetic modifications under high glucose conditions. *Exp Cell Res*, 324(1), 75-83 (2014)
DOI: 10.1016/j.yexcr.2014.03.019
152. K. Sato-Kusubata, Y. Jiang, Y. Ueno and T. H. Chun: Adipogenic histone mark regulation by matrix metalloproteinase 14 in collagen-rich microenvironments. *Mol Endocrinol*, 25(5), 745-53 (2011)
DOI: 10.1210/me.2010-0429
153. M. Poplineau, J. Dufer, F. Antonicelli and A. Trussardi-Regnier: Epigenetic regulation of proMMP-1 expression in the HT1080 human fibrosarcoma cell line. *Int J Oncol*, 38(6), 1713-8 (2011)
154. R. A. Kowluru, J. M. Santos and M. Mishra: Epigenetic modifications and diabetic retinopathy. *Biomed Res Int*, 2013, 635284 (2013)
DOI: 10.1155/2013/635284
155. M. Osaki, A. Inaba, K. Nishikawa, Y. Sugimoto, K. Shomori, T. Inoue, M. Oshimura and H. Ito: Cysteine-rich protein 61 suppresses cell invasion via down-regulation of matrix metalloproteinase-7 expression in the human gastric carcinoma cell line MKN-45. *Mol Med Rep*, 3(4), 711-5 (2010)
DOI: 10.3892/mmr_00000322
156. N. Narayanan, N. Tyagi, A. Shah, S. Pagni and S. C. Tyagi: Hyperhomocysteinemia during aortic aneurysm, a plausible role of epigenetics. *Int J Physiol Pathophysiol Pharmacol*, 5(1), 32-42 (2013)
157. K. Chen and N. Rajewsky: The evolution of gene regulation by transcription factors and microRNAs. *Nat Rev Genet*, 8(2), 93-103 (2007)
DOI: 10.1038/nrg1990
158. K. C. Chen, Y. S. Wang, C. Y. Hu, W. C. Chang, Y. C. Liao, C. Y. Dai and S. H. Juo: OxLDL up-regulates microRNA-29b, leading to epigenetic modifications of MMP-2/MMP-9 genes: a novel mechanism for cardiovascular diseases. *FASEB J*, 25(5), 1718-28 (2011)
DOI: 10.1096/fj.10-174904
159. S. T. Boon RA, Heydt S, Fischer A, Hergenreider E, Horrevoets AJ, Vinciguerra M, Rosenthal N, Sciacca S, Pilato M, van Heijningen P, Essers J, Brandes RP, Zeiher AM, Dimmeler S.: Micro-RNA-29 in aortic dilation: implications for aneurysm formation. *Circ Res* 109(10), 1115-9 (2011)
DOI: 10.1161/CIRCRESAHA.111.255737
160. K. C. Chen, Y. C. Liao, I. C. Hsieh, Y. S. Wang, C. Y. Hu and S. H. Juo: OxLDL causes both epigenetic modification and signaling regulation on the microRNA-29b gene: novel mechanisms for cardiovascular diseases. *J Mol Cell Cardiol*, 52(3), 587-95 (2012)
DOI: 10.1016/j.yjmcc.2011.12.005
161. M. P. Turunen and S. Yla-Herttuala: Epigenetic regulation of key vascular genes and growth factors. *Cardiovasc Res*, 90(3), 441-446 (2011)
DOI: 10.1093/cvr/cvr109
162. D. Wu, H. Pan, Y. Zhou, J. Zhou, Y. Fan and P. Qu: microRNA-133b downregulation and inhibition of cell proliferation, migration and invasion by targeting matrix metalloproteinase-9 in renal cell carcinoma. *Mol Med Rep*, 9(6), 2491-8 (2014)

163. X. Zhou, Y. Ren, A. Liu, L. Han, K. Zhang, S. Li, P. Li, C. Kang, X. Wang and L. Zhang: STAT3 inhibitor WP1066 attenuates miRNA-21 to suppress human oral squamous cell carcinoma growth in vitro and in vivo. *Oncol Rep*, 31(5), 2173-80 (2014)
164. Z. Ye, L. Jingzhong, L. Yangbo, C. Lei and Y. Jiandong: Propofol inhibits proliferation and invasion of osteosarcoma cells by regulation of microRNA-143 expression. *Oncol Res*, 21(4), 201-7 (2014)
DOI: 10.3727/096504014X13890370410203
165. P. Ye, J. Liu, F. He, W. Xu and K. Yao: Hypoxia-induced deregulation of miR-126 and its regulative effect on VEGF and MMP-9 expression. *Int J Med Sci*, 11(1), 17-23 (2014)
DOI: 10.7150/ijms.7329
166. J. M. Siddesha, A. J. Valente, T. Yoshida, S. S. Sakamuri, P. Delafontaine, H. Iba, M. Noda and B. Chandrasekar: Docosahexaenoic acid reverses angiotensin II-induced RECK suppression and cardiac fibroblast migration. *Cell Signal*, 26(5), 933-41 (2014)
DOI: 10.1016/j.cellsig.2014.01.005
167. C. S. Palmieri D, Geroldi A, Mura M, Mandich P, Palombo D: TNF α induces the expression of genes associated with endothelial dysfunction through p38MAPK-mediated down-regulation of miR-149. *Biochem Biophys Res Commun*, 443(1), 246-51 (2014)
DOI: 10.1016/j.bbrc.2013.11.092
168. H. Y. Zhang, M. Qi, S. W. Li, T. Qi, H. Mei, K. Huang, L. D. Zheng and Q. S. Tong: microRNA-9 Targets Matrix Metalloproteinase 14 to Inhibit Invasion, Metastasis, and Angiogenesis of Neuroblastoma Cells. *Mol Canc Ther*, 11(7), 1454-1466 (2012)
DOI: 10.1158/1535-7163.MCT-12-0001
169. V. Siragam, Z. J. Rutnam, W. Yang, L. Fang, L. Luo, X. Yang, M. Li, Z. Deng, J. Qian, C. Peng and B. B. Yang: MicroRNA miR-98 inhibits tumor angiogenesis and invasion by targeting activin receptor-like kinase-4 and matrix metalloproteinase-11. *Oncotarget*, 3(11), 1370-85 (2012)
170. R. Morales, S. Perrier, J. M. Florent, J. Beltra, S. Dufour, I. De Mendez, P. Manceau, A. Tertre, F. Moreau, D. Compere, A. C. Dublanchet and M. O'Gara: Crystal structures of novel non-peptidic, non-zinc chelating inhibitors bound to MMP-12. *J Mol Biol*, 341(4), 1063-76 (2004)
DOI: 10.1016/j.jmb.2004.06.039
171. S. T. Huang, R. C. Yang, H. T. Wu, C. N. Wang and J. H. S. Pang: Zinc-Chelation Contributes to the Anti-Angiogenic Effect of Ellagic Acid on Inhibiting MMP-2 Activity, Cell Migration and Tube Formation. *PLoS One*, 6(5) (2011)
DOI: 10.1371/journal.pone.0018986
172. H. S. Rasmussen and P. P. McCann: Matrix metalloproteinase inhibition as a novel anticancer strategy: A review with special focus on batimastat and marimastat. *Pharmacol Ther*, 75(1), 69-75 (1997)
DOI: 10.1016/S0163-7258(97)00023-5
173. S. S. Kocer, S. G. Walker, B. Zerler, L. M. Golub and S. R. Simon: Metalloproteinase inhibitors, nonantimicrobial chemically modified tetracyclines, and ilomastat block *Bacillus anthracis* lethal factor activity in viable cells. *Infect Immun*, 73(11), 7548-57 (2005)
DOI: 10.1128/IAI.73.11.7548-7557.2005
174. E. Koivunen, W. Arap, H. Valtanen, A. Rainisalo, O. P. Medina, P. Heikkila, C. Kantor, C. G. Gahmberg, T. Salo, Y. T. Kontinen, T. Sorsa, E. Ruoslahti and R. Pasqualini: Tumor targeting with a selective gelatinase inhibitor. *Nat Biotechnol*, 17(8), 768-74 (1999)
DOI: 10.1038/11703
175. M. M. Castro, A. D. Kandasamy, N. Youssef and R. Schulz: Matrix metalloproteinase inhibitor properties of tetracyclines: therapeutic potential in cardiovascular diseases. *Pharmacol Res*, 64(6), 551-60 (2011)
DOI: 10.1016/j.phrs.2011.05.005
176. Z. X. Luan, A. J. Chase and A. C. Newby: Statins inhibit secretion of metalloproteinases-1,-2,-3, and-9 from vascular smooth muscle cells and macrophages. *Arterioscler Thromb Vasc Biol*, 23(5), 769-775 (2003)
DOI: 10.1161/01.ATV.0000068646.76823.AE
177. H. Mitani, K. Egashira and M. Kimura: HMG-CoA reductase inhibitor, fluvastatin, has cholesterol-lowering independent "direct" effects on atherosclerotic vessels in high cholesterol diet-fed rabbits. *Pharmacol Res*, 48(5), 417-427 (2003)
DOI: 10.1016/S1043-6618(03)00184-1
178. J. N. Freskos, B. Asmelash, K. R. Gaston, A. Karwa, T. A. Marzan, M. A. Nickols, T. E. Rogers, T. Schoenstein, C. J. Sympton and

- B. Vu: Design and synthesis of MMP inhibitors with appended fluorescent tags for imaging and visualization of matrix metalloproteinase enzymes. *Bioorg Med Chem Lett*, 23(20), 5566-5570 (2013)
DOI: 10.1016/j.bmcl.2013.08.050
179. S. Santamaria, E. Nuti, G. Cercignani, L. Marinelli, V. La Pietra, E. Novellino and A. Rossello: N-O-Isopropyl sulfonamido-based hydroxamates: Kinetic characterisation of a series of MMP-12/MMP-13 dual target inhibitors. *Biochem Pharmacol*, 84(6), 813-820 (2012)
DOI: 10.1016/j.bcp.2012.06.026
 180. V. La Pietra, L. Marinelli, S. Cosconati, F. S. Di Leva, E. Nuti, S. Santamaria, I. Pugliesi, M. Morelli, F. Casalini, A. Rossello, C. La Motta, S. Taliani, R. Visse, H. Nagase, F. da Settimo and E. Novellino: Identification of novel molecular scaffolds for the design of MMP-13 inhibitors: a first round of lead optimization. *Eur J of Med Chem*, 47(1), 143-52 (2012)
DOI: 10.1016/j.ejmech.2011.10.035
 181. P. Jain, C. Saravanan and S. K. Singh: Sulphonamides: Deserving class as MMP inhibitors? *Eur J Med Chem*, 60, 89-100 (2013)
DOI: 10.1016/j.ejmech.2012.10.016
 182. X. Xu, M. Mikhailova, Z. Chen, S. Pal, T. K. Robichaud, E. M. Lafer, S. Baber and B. Steffensen: Peptide from the C-terminal domain of tissue inhibitor of matrix metalloproteinases-2 (TIMP-2) inhibits membrane activation of matrix metalloproteinase-2 (MMP-2). *Matrix Biol*, 30(7-8), 404-12 (2011)
DOI: 10.1016/j.matbio.2011.07.001
 183. O. Nicolotti, M. Catto, I. Giangreco, M. Barletta, F. Leonetti, A. Stefanachi, L. Pisani, S. Cellamare, P. Tortorella, F. Loiodice and A. Carotti: Design, synthesis and biological evaluation of 5-hydroxy, 5-substituted-pyrimidine-2,4,6-triones as potent inhibitors of gelatinases MMP-2 and MMP-9. *Eur J Med Chem*, 58, 368-376 (2012)
DOI: 10.1016/j.ejmech.2012.09.036
 184. A. Heim-Riether, S. J. Taylor, S. Liang, D. A. Gao, Z. Xiong, E. Michael August, B. K. Collins, B. T. Farmer, 2nd, K. Haverty, M. Hill-Drzewi, H. D. Junker, S. Mariana Margarit, N. Moss, T. Neumann, J. R. Proudfoot, L. S. Keenan, R. Sekul, Q. Zhang, J. Li and N. A. Farrow: Improving potency and selectivity of a new class of non-Zn-chelating MMP-13 inhibitors. *Bioorg Med Chem Lett*, 19(18), 5321-4 (2009)
DOI: 10.1016/j.bmcl.2009.07.151
 185. D. A. Gao, Z. Xiong, A. Heim-Riether, L. Amodeo, E. M. August, X. Cao, L. Ciccarelli, B. K. Collins, K. Harrington, K. Haverty, M. Hill-Drzewi, X. Li, S. Liang, S. M. Margarit, N. Moss, N. Nagaraja, J. Proudfoot, R. Roman, S. Schlyer, L. S. Keenan, S. Taylor, B. Wellenzohn, D. Wiedenmayer, J. Li and N. A. Farrow: SAR studies of non-zinc-chelating MMP-13 inhibitors: improving selectivity and metabolic stability. *Bioorg Med Chem Lett*, 20(17), 5039-43 (2010)
DOI: 10.1016/j.bmcl.2010.07.036
 186. H. Yuan, W. Q. Lu, L. Y. Wang, L. Shan, H. L. Li, J. Huang, Q. Y. Sun and W. D. Zhang: Synthesis of derivatives of methyl rosmarinate and their inhibitory activities against matrix metalloproteinase-1 (MMP-1). *Eur J Med Chem*, 62, 148-157 (2013)
DOI: 10.1016/j.ejmech.2012.09.047
 187. A. R. Farina, L. Cappabianca, N. Di Ianni, P. Ruggeri, M. Ragone, S. Merolle, A. Gulino and A. R. Mackay: Alendronate promotes plasmin-mediated MMP-9 inactivation by exposing cryptic plasmin degradation sites within the MMP-9 catalytic domain. *FEBS Lett*, 586(16), 2366-2374 (2012)
DOI: 10.1016/j.febslet.2012.05.048
 188. S. Y. Chuang, S. H. Yang, T. Y. Chen and J. H. S. Pang: Cilostazol inhibits matrix invasion and modulates the gene expressions of MMP-9 and TIMP-1 in PMA-differentiated THP-1 cells. *Eur J Pharmacol*, 670(2-3), 419-426 (2011)
DOI: 10.1016/j.ejphar.2011.08.040
 189. M. Okada, R. Kikuzuki, T. Harada, Y. Hori, H. Yamawaki and Y. Hara: Captopril attenuates matrix metalloproteinase-2 and -9 in monocrotaline-induced right ventricular hypertrophy in rats. *J Pharmacol Sci*, 108(4), 487-94 (2008)
DOI: 10.1254/jphs.08174FP
 190. D. Yamamoto, S. Takai and M. Miyazaki: Inhibitory profiles of captopril on matrix metalloproteinase-9 activity. *Eur J Pharmacol*, 588(2-3), 277-9 (2008)
DOI: 10.1016/j.ejphar.2008.04.031

191. I. K. Onal, B. Altun, E. D. Onal, A. Kirkpantur, S. Gul Oz and C. Turgan: Serum levels of MMP-9 and TIMP-1 in primary hypertension and effect of antihypertensive treatment. *Eur J Intern Med*, 20(4), 369-72 (2009)
DOI: 10.1016/j.ejim.2008.10.003
192. L. B. Kuntze, R. C. Antonio, T. C. Izidoro-Toledo, C. A. Meschiari, J. E. Tanus-Santos and R. F. Gerlach: Captopril and Lisinopril Only Inhibit Matrix Metalloproteinase-2 (MMP-2) Activity at Millimolar Concentrations. *Basic Clin Pharmacol Toxicol*, 114(3), 233-239 (2014)
DOI: 10.1111/bcpt.12151
193. J. P. Wang, Q. Zhang, X. H. Mei and X. Z. Zhang: Hydroxysafflor yellow A attenuates left ventricular remodeling after pressure overload-induced cardiac hypertrophy in rats. *Pharmaceut Biol*, 52(1), 31-35 (2014)
DOI: 10.3109/13880209.2013.805791
194. C. W. Lin, P. N. Chen, M. K. Chen, W. E. Yang, C. H. Tang, S. F. Yang and Y. S. Hsieh: Kaempferol Reduces Matrix Metalloproteinase-2 Expression by Down-Regulating ERK1/2 and the Activator Protein-1 Signaling Pathways in Oral Cancer Cells. *PLoS One*, 8(11) (2013)
DOI: 10.1371/journal.pone.0080883
195. P. K. Kamat, A. Kalani, S. Givvimani, P. B. Sathnur, S. C. Tyagi and N. Tyagi: Hydrogen Sulfide Attenuates Neurodegeneration and Neurovascular Dysfunction Induced by Intracerebral-Administered Homocysteine in Mice. *Neuroscience*, 252, 302-319 (2013)
DOI: 10.1016/j.neuroscience.2013.07.051
196. U. Sen, C. Munjal, N. Qipshidze, O. Abe, R. Gargoum and S. C. Tyagi: Hydrogen sulfide regulates homocysteine-mediated glomerulosclerosis. *Am J Nephrol*, 31(5), 442-55 (2010)
DOI: 10.1159/000296717
197. U. Sen, P. Basu, O. A. Abe, S. Givvimani, N. Tyagi, N. Metreveli, K. S. Shah, J. C. Passmore and S. C. Tyagi: Hydrogen sulfide ameliorates hyperhomocysteinemia-associated chronic renal failure. *Am J Physiol Renal Physiol*, 297(2), F410-9 (2009)
DOI: 10.1152/ajprenal.00145.2009
198. B. Lavin, M. Gomez, O. M. Pello, B. Castejon, M. J. Piedras, M. Saura and C. Zaragoza: Nitric Oxide Prevents Aortic Neointimal Hyperplasia by Controlling Macrophage Polarization. *Arterioscler Thromb Vasc Biol*, 34(8), 1739-+ (2014)
199. S. Zucker, M. Drews, C. Conner, H. D. Foda, Y. A. DeClerck, K. E. Langley, W. F. Bahou, A. J. Docherty and J. Cao: Tissue inhibitor of metalloproteinase-2 (TIMP-2) binds to the catalytic domain of the cell surface receptor, membrane type 1-matrix metalloproteinase 1 (MT1-MMP). *J Biol Chem*, 273(2), 1216-22 (1998)
DOI: 10.1074/jbc.273.2.1216
200. C. M. Overall, E. Tam, G. A. McQuibban, C. Morrison, U. M. Wallon, H. F. Bigg, A. E. King and C. R. Roberts: Domain interactions in the gelatinase A-TIMP-2-MT1-MMP activation complex. The ectodomain of the 44-kDa form of membrane type-1 matrix metalloproteinase does not modulate gelatinase A activation. *J Biol Chem*, 275(50), 39497-506 (2000)
DOI: 10.1074/jbc.M005932200
201. H. S. Kai, G. S. Butler, C. J. Morrison, A. E. King, G. R. Pelman and C. M. Overall: Utilization of a novel recombinant myoglobin fusion protein expression system to characterize the tissue inhibitor of metalloproteinase (TIMP)-4 and TIMP-2 C-terminal domain and tails by mutagenesis. The importance of acidic residues in binding the MMP-2 hemopexin C-domain. *J Biol Chem*, 277(50), 48696-707 (2002)
DOI: 10.1074/jbc.M209177200
202. G. Sawicki, V. Menon and B. I. Jugdutt: Improved balance between TIMP-3 and MMP-9 after regional myocardial ischemia-reperfusion during AT1 receptor blockade. *J Card Fail*, 10(5), 442-9 (2004)
DOI: 10.1016/j.cardfail.2004.01.012
203. T. Sakamoto and M. Seiki: Cytoplasmic tail of MT1-MMP regulates macrophage motility independently from its protease activity. *Genes Cells*, 14(5), 617-26 (2009)
DOI: 10.1111/j.1365-2443.2009.01293.x
204. I. Kazes, I. Elalamy, J. D. Sraer, M. Hatmi and G. Nguyen: Platelet release of trimolecular complex components MT1-MMP/TIMP2/ MMP2: involvement in MMP2 activation and platelet aggregation. *Blood*, 96(9), 3064-9 (2000)
205. Z. Yin, A. A. Sada, O. M. Reslan, N. Narula and R. A. Khalil: Increased MMPs

- expression and decreased contraction in the rat myometrium during pregnancy and in response to prolonged stretch and sex hormones. *Am J Physiol Endocrinol Metab*, 303(1), E55-70 (2012)
DOI: 10.1152/ajpendo.00553.2011
206. V. E. de Meijer, D. Y. Sverdllov, Y. Popov, H. D. Le, J. A. Meisel, V. Nose, D. Schuppan and M. Puder: Broad-spectrum matrix metalloproteinase inhibition curbs inflammation and liver injury but aggravates experimental liver fibrosis in mice. *PLoS One*, 5(6), e11256 (2010)
DOI: 10.1371/journal.pone.0011256
 207. P. Bencsik, J. Paloczi, G. F. Kocsis, J. Pipis, I. Belec, Z. V. Varga, C. Csonka, A. Gorbe, T. Csont and P. Ferdinandy: Moderate inhibition of myocardial matrix metalloproteinase-2 by ilomastat is cardioprotective. *Pharmacol Res: the official journal of the Italian Pharmacological Society*, 80, 36-42 (2014)
DOI: 10.1016/j.phrs.2013.12.007
 208. X. Zhang, J. Bresee, G. B. Fields and W. B. Edwards: Near-infrared triple-helical peptide with quenched fluorophores for optical imaging of MMP-2 and MMP-9 proteolytic activity in vivo. *Bioorg Med Chem Lett*, 24(16), 3786-90 (2014)
DOI: 10.1016/j.bmcl.2014.06.072
 209. Z. Luan, A. J. Chase and A. C. Newby: Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. *Arterioscler Thromb Vasc Biol*, 23(5), 769-75 (2003)
DOI: 10.1161/01.ATV.0000068646.76823.AE
 210. H. Nagashima, Y. Aoka, Y. Sakomura, A. Sakuta, S. Aomi, N. Ishizuka, N. Hagiwara, M. Kawana and H. Kasanuki: A 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, cerivastatin, suppresses production of matrix metalloproteinase-9 in human abdominal aortic aneurysm wall. *J Vasc Surg*, 36(1), 158-63 (2002)
DOI: 10.1067/mva.2002.123680
 211. L. Vincent, W. Chen, L. Hong, F. Mirshahi, Z. Mishal, T. Mirshahi-Khorassani, J. P. Vannier, J. Soria and C. Soria: Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: contribution to its anti-angiogenic effect. *FEBS Lett*, 495(3), 159-66 (2001)
DOI: 10.1016/S0014-5793(01)02337-7
 212. Y. J. Chen and L. S. Chang: Simvastatin induces NFkappaB/p65 down-regulation and JNK1/c-Jun/ATF-2 activation, leading to matrix metalloproteinase-9 (MMP-9) but not MMP-2 down-regulation in human leukemia cells. *Biochem Pharmacol*, 92(4), 530-43 (2014)
DOI: 10.1016/j.bcp.2014.09.026
 213. K. A. Manu, M. K. Shanmugam, F. Li, L. Chen, K. S. Siveen, K. S. Ahn, A. P. Kumar and G. Sethi: Simvastatin sensitizes human gastric cancer xenograft in nude mice to capecitabine by suppressing nuclear factor-kappa B-regulated gene products. *J Mol Med (Berl)*, 92(3), 267-76 (2014)
DOI: 10.1007/s00109-013-1095-0
 214. V. L. Andrade, I. B. do Valle and V. C. Sandrim: Simvastatin therapy decreases MMP-9 levels in obese women. *J Clin Pharmacol*, 53(10), 1072-7 (2013)
DOI: 10.1002/jcph.146
 215. R. Janardhanan, B. Yang, P. Vohra, B. Roy, S. Withers, S. Bhattacharya, J. Mandrekar, H. Kong, E. B. Leof, D. Mukhopadhyay and S. Misra: Simvastatin reduces venous stenosis formation in a murine hemodialysis vascular access model. *Kidney Int*, 84(2), 338-52 (2013)
DOI: 10.1038/ki.2013.112
 216. S. Kang, E. S. Kim and A. Moon: Simvastatin and lovastatin inhibit breast cell invasion induced by H-Ras. *Oncol Rep*, 21(5), 1317-22 (2009)
 217. A. Slawinska-Brych, B. Zdzisinska and M. Kandefer-Szerszen: Fluvastatin inhibits growth and alters the malignant phenotype of the C6 glioma cell line. *Pharmacol Rep*, 66(1), 121-9 (2014)
DOI: 10.1016/j.pharep.2014.01.002
 218. H. Ozaki, Y. Miyashita, H. Watanabe and K. Shirai: Enhancement of MMP-9 activity in THP-1 cells by 7-ketocholesterol and its suppression by the HMG-CoA reductase inhibitor fluvastatin. *J Atheroscler Thromb*, 12(6), 308-14 (2005)
DOI: 10.5551/jat.12.308
 219. H. B. Leu, J. W. Chen, T. C. Wu, Y. A. Ding, S. J. Lin and M. J. Charng: Effects of fluvastatin, an HMG-CoA reductase inhibitor, on serum levels of interleukin-18 and matrix metalloproteinase-9 in patients with hypercholesterolemia. *Clin Cardiol*, 28(9), 423-8 (2005)
DOI: 10.1002/clc.4960280907

220. G. Pochetti, E. Gavuzzo, C. Campestre, M. Agamennone, P. Tortorella, V. Consalvi, C. Gallina, O. Hiller, H. Tschesche, P. A. Tucker and F. Mazza: Structural insight into the stereoselective inhibition of MMP-8 by enantiomeric sulfonamide phosphonates. *J Med Chem*, 49(3), 923-31 (2006)
DOI: 10.1021/jm050787+
221. D. P. Becker, C. I. Villamil, T. E. Barta, L. J. Bedell, T. L. Boehm, G. A. Decrescenzo, J. N. Freskos, D. P. Getman, S. Hockerman, R. Heintz, S. C. Howard, M. H. Li, J. J. McDonald, C. P. Carron, C. L. Funckes-Shippy, P. P. Mehta, G. E. Munie and C. A. Swearingen: Synthesis and structure-activity relationships of beta- and alpha-piperidine sulfone hydroxamic acid matrix metalloproteinase inhibitors with oral antitumor efficacy. *J Med Chem*, 48(21), 6713-30 (2005)
DOI: 10.1021/jm0500875
222. M. Mori, A. Massaro, V. Calderone, M. Fragai, C. Luchinat and A. Mordini: Discovery of a New Class of Potent MMP Inhibitors by Structure-Based Optimization of the Arylsulfonamide Scaffold. *ACS Med Chem Lett*, 4(6), 565-9 (2013)
DOI: 10.1021/ml300446a
223. H. Yuan, W. Lu, L. Wang, L. Shan, H. Li, J. Huang, Q. Sun and W. Zhang: Synthesis of derivatives of methyl rosmarinate and their inhibitory activities against matrix metalloproteinase-1 (MMP-1). *Eur J Med Chem*, 62, 148-57 (2013)
DOI: 10.1016/j.ejmech.2012.09.047
224. Y. Luo, L. Zhang, W. Y. Wang, Q. F. Hu, H. P. Song, Y. L. Su and Y. Z. Zhang: Alendronate retards the progression of lumbar intervertebral disc degeneration in ovariectomized rats. *Bone*, 55(2), 439-48 (2013)
DOI: 10.1016/j.bone.2013.03.002
225. Y. Omote, K. Deguchi, S. Kono, N. Liu, W. Liu, T. Kurata, T. Yamashita, Y. Ikeda and K. Abe: Neurovascular protection of cilostazol in stroke-prone spontaneous hypertensive rats associated with angiogenesis and pericyte proliferation. *J Neurosci Res*, 92(3), 369-74 (2014)
DOI: 10.1002/jnr.23327
226. B. C. Yu, D. S. Lee, S. M. Bae, W. K. Jung, J. H. Chun, S. H. Urm, D. Y. Lee, S. J. Heo, S. G. Park, S. K. Seo, J. W. Yang, J. S. Choi, W. S. Park and I. W. Choi: The effect of cilostazol on the expression of matrix metalloproteinase-1 and type I procollagen in ultraviolet-irradiated human dermal fibroblasts. *Life Sci*, 92(4-5), 282-8 (2013)
DOI: 10.1016/j.lfs.2012.12.011
227. M. Ishiguro, K. Mishiro, Y. Fujiwara, H. Chen, H. Izuta, K. Tsuruma, M. Shimazawa, S. Yoshimura, M. Satoh, T. Iwama and H. Hara: Phosphodiesterase-III inhibitor prevents hemorrhagic transformation induced by focal cerebral ischemia in mice treated with tPA. *PLoS One*, 5(12), e15178 (2010)
DOI: 10.1371/journal.pone.0015178
228. L. Devel, F. Beau, M. Amoura, L. Vera, E. Cassar-Lajeunesse, S. Garcia, B. Czarny, E. A. Stura and V. Dive: Simple pseudo-dipeptides with a P2' glutamate: a novel inhibitor family of matrix metalloproteases and other metzincins. *J Biol Chem*, 287(32), 26647-56 (2012)
DOI: 10.1074/jbc.M112.380782
229. L. Devel, S. Garcia, B. Czarny, F. Beau, E. LaJeunesse, L. Vera, D. Georgiadis, E. Stura and V. Dive: Insights from selective non-phosphinic inhibitors of MMP-12 tailored to fit with an S1' loop canonical conformation. *J Biol Chem*, 285(46), 35900-9 (2010)
DOI: 10.1074/jbc.M110.139634
230. J. Johnson, S. George, A. Newby, and C. Jackson. Divergent effects of matrix metalloproteinases 3, 7, 9, 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries. *PNAS*, 103(42), 15575-80 (2005)
DOI: 10.1073/pnas.0506201102
231. L. Kevorkian, D. Young, C. Darrah, S. Donell, L. Shepstone, S. Porter, S. Brockbank, D. Edwards, A. Parker, I. Clark. Expression profiling of metalloproteinases and their inhibitors in cartilage. *Arthritis Rheum*, 50(1), 131-41 (2004)
DOI: 10.1002/art.11433

Abbreviations: AAA: Abdominal aortic aneurysm AT1: Angiotensin II receptor type 1 BBB: Blood brain barrier BWC: Brain water content COPD: Chronic obstructive pulmonary disease DNMT1: DNA methyltransferase 1 DVT: Deep-vein thrombosis E2F1: is a transcription factor ECAS: Extracranial atherosclerosis ECM: Extracellular matrix ECs: Endothelial cells FRET: Fluorescence resonance energy transfer FSS: Fluid shear

stress H3K9: Histone 3 tri-methylated at lysine 9H3K9ac: H3 lysine 9 acetylation HDAC1: Histone deacetylase 1 HDL: High-density lipoproteinHSP: Henoch-Scho"nlein purpura ICAS: Intracranial atherosclerosis ILA: intracranial large artery atherosclerosis L-NAME: L-NG-Nitroarginine Methyl Ester LSD1: Lysine-specific demethylase 1MBD2: Methyl binding domain 2 NO: Nitric oxideNOS: Nitric oxide synthaseNox2: NADPH oxidase 2 OxLDL: Oxidized low-density lipoprotein PLA2: Phospholipase A2 RANKL: Receptor activator of nuclear factor kappa-B ligand siRNA silencing of GSK-3 β inhibited the phosphorylation of H3SIRT1: Deacetylase Sirtuin-1 TACE: Tumor necrosis factor- α -converting enzyme (also known as ADAM17)TFPI2: Tissue factor pathway inhibitor 2 TIMPs: Tissue inhibitor of metalloproteinasesTSA: Trichostatin A TSP-1: Thrombospondin-1 VEGF: Vascular endothelial growth factor VEGFR2: Vascular endothelial growth factor receptor-2 VSMC(s): Vascular smooth muscle cell(s)

Key Words: MMPs, TIMPs, miRNA, Epigenetics, ExtracellularMatrix,Atherosclerosis, Cardiovascular, Review

Send correspondence to: Utpal Sen, Department of Physiology and Biophysics, University of Louisville School of Medicine, 500 South Preston St, Louisville, KY-40292, Tel: 502-852-2030, Fax: 502-852-6239, E-mail: u0sen001@louisville.edu